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Infectious diseases are one of the leading causes of death globally for adults and children and 
remains a major public health issue for developed and developing countries. Although 
antibiotics transformed the treatment of infections, saving millions of lives, eighty years after 
their discovery, their usefulness is seriously threatened by antimicrobial resistance. This rising 
development of antibiotic resistance to presently used antibiotics and the decline in 
introduction of new antibiotic drugs is unmistakably a risk to human health worldwide. It is 
therefore essential that alternative novel antimicrobial therapeutic strategies are explored to 
address the imminent crisis associated with conventional antibiotics. The quest for novel and 
effective approaches to enhance antimicrobial drug therapy is therefore identified globally as 
a key focus area of research priority. Antimicrobial materials such as novel dendrimer silver 
salts and a novel star polymer for application in silver nanoparticles, might be a favourable 
approach to overcome the existing challenges related to antibiotic therapy due to their unique 
properties. PETIM silver salts have not been studied and there are no PEG star polymers 
available for stabilisation of silver nanoparticles. The aims of the study were therefore to: (1) 
explore the potential of novel antimicrobial dendrimer silver salts for enhanced antimicrobial 
activity and (2) explore the potential of a novel star shaped polymer for use as a stabilising 
agent in the preparation of silver nanoparticles. 
The purpose of aim one was to exploit the multiple peripheral functionalities of G1 PETIM 
dendron and dendrimers for the formation of silver salts containing multiple silver ions in a 
single molecule for enhanced antimicrobial activity at the lowest possible concentration. In 
order to accomplish the first aim, G1 PETIM dendron, dendrimers and their silver salts were 
synthesised and characterised by FT-IR, 1H NMR and 13C NMR. PETIM silver salts were 
evaluated against Hep G2, SKBR-3 and HT-29 cell lines for their cytotoxicity using the MTT 
assay. The G1 PETIM dendron/dendrimers, silver nitrate and silver salts of the G1 dendron 
(compound 13), G1 dendrimer with an aromatic core (compound 14) and an oxygen core 
(compound 15) were evaluated for activity against S. aureus and methicillin-resistant S. aureus 
(MRSA) by the broth dilution method. PETIM silver salts were found to be non-cytotoxic even 
up to 100 µg/ml. Minimum inhibitory concentration values of compounds 13, 14 and 15 against 
S. aureus were 52.1, 41.7, and 20.8 μg/ml while against MRSA they were 125.0, 26.0 and 62.5 
ix 
μg/ml respectively. The calculated fractional inhibitory concentration index further indicated 
that compound 14 specifically displayed additive effects against S. aureus and synergism 
against MRSA. The enhanced antimicrobial activities of the PETIM dendron/dendrimer-silver 
salts against both sensitive and resistant bacterial strains widen the pool of available 
pharmaceutical materials for optimising treatment of bacterial infections. 
The purpose of aim two was to synthesise a G1 PETIM dendrimer derived 6-arm polyethylene 
glycol (PEG) star polymer for application as a stabiliser for silver nanoparticles. In order to 
accomplish the second aim the synthesised star polymer was characterised using FT-IR, 1H, 
13C and XRD analysis. Silver nanoparticles were prepared via chemical reduction using the 
star polymer as a stabiliser and their formation was verified using UV-vis spectroscopy, 
dynamic light scattering, transmission electron microscopy and XRD analysis. The synthesised 
star polymer and star polymer stabilised silver nanoparticles were evaluated for their 
cytotoxicity against MCF-7, HeLa and Hep G2 cell lines using the MTT assay. The silver 
nanoparticles, silver nitrate, star polymer and a physical mixture of the latter two were 
evaluated for antibacterial activity against S. aureus, MRSA, E. coli and P aeruginosa. The 
synthesised silver nanoparticles were non-agglomerated, spherical and monodisperse with an 
average particle size of 36.44 ± 2.51 nm, and found to be non-cytotoxic even up to 100 µg/ml. 
The minimum inhibitory concentration values against S. aureus and MRSA (Gram-positive 
bacteria) were 18.5 and 74 µg/ml respectively, and against E.coli and P. aeruginosa (Gram-
negative bacteria), the values were 9.25 and 74 µg/ml respectively. These low MIC values 
confirmed that the silver nanoparticles retained their antibacterial potential even upon 
stabilisation by the star polymer. These results suggested that the synthesised star polymer is 
an attractive biocompatible material for the stabilisation of silver nanoparticles. 
The results obtained in this study confirm the potential formation of novel materials, such as 
the PETIM silver salts as well as the star polymer stabilised silver nanoparticles. They both 
display good antimicrobial activity against sensitive and resistant bacterial strains. These are 
new materials with the potential for commercialisation. This study is the building block for 
future research and can also be explored for application in nanomedicine and the biomedical 
sciences. 
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CHAPTER 1. INTRODUCTION 
1.1 Introduction 
This chapter outlines the background of this study, including the present status of infectious 
diseases and the difficulties associated with current antibiotic therapy. It explores the use of novel 
polymeric materials to overcome the challenges related to antimicrobial resistance, and indicates 
the aims and objectives. The significance and novelty of the study are also highlighted.  
1.2 Background to the study 
Infectious diseases, a major percentage of which are of bacterial origin, are one of the foremost 
causes of death worldwide for children and adults, and remain an important public health problem 
for both developed and developing countries (Lozano et al., 2013). In 2013, approximately half of 
the 6.3 million children who died before the age of 5 did so as a result of infectious causes, and 
nearly two-fifths passed away during the neonatal period (Liu et al., 2015). According to the WHO, 
on April 30, 2014, inconsequential infections and injuries, which were easily treatable for years, 
were again a major threat to public health (WHO). The introduction of antibiotics was one of the 
most significant interventions to decrease diseases, has saved millions of human and animal lives, 
and contributed significantly to the progress of modern medicinal procedures (Ray et al., 2012; 
Xiong et al., 2014).  
However, eighty years subsequent to their discovery, their usefulness is compromised by 
antimicrobial resistance (AMR) (Cars et al., 2011) that threatens to invalidate the use of even the 
most effective antibiotics, which will result in patients suffering and/or dying owing to infection 
control failure, and lead to escalated health care costs (Huh and Kwon, 2011). Worldwide, resistant 
bacterial strains, for example methicillin-resistant Staphylococcus aureus (MRSA) (Cohen, 2000), 
vancomycin-resistant Enterococcus (VRE) (Wood et al., 1996) and vancomycin-resistant 
Staphylococcus aureus (VRSA), (Périchon and Courvalin, 2009), have become noteworthy threats 
in community settings and hospitals to treat infections. Additionally, if present rising trends in 
AMR continue, numerous vital procedures, for example organ transplantation, cancer 
chemotherapy, hip and other joint replacements, may  no longer be performed due to fear that the 
associated compromised immune system could place the patients at a severe threat of attaining 
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infections that are difficult to treat and eventually fatal (Heymann and Rodier, 2001). Furthermore, 
they are affected by insufficient drug concentrations at the target infection sites, increased 
frequency of administration, severe side effects, as well as poor patient compliance, all of which 
which compromises drug therapy and contributes significantly to AMR (Huh and Kwon, 2011; 
Sharma et al., 2012). The global AMR crisis is further intensified by the decline in the development 
of novel antibiotics by pharmaceutical companies (Cars et al., 2008). The deterioration in drug 
development is a result of high costs and lengthy delays related to developing a novel chemical 
entity, high attrition rates at final testing, and growing AMR to newly established drugs, which 
makes discovering a new drug extremely costly and restricts the return on investment (Huh and 
Kwon, 2011; Okeke et al., 2005).  
It is therefore imperative that alternative novel antimicrobial therapeutic strategies are explored to 
address the looming crisis with conventional antibiotics. Alternative options currently being 
investigated are novel nanosized drug delivery systems, which could be a promising approach to 
overcome the current challenges associated with antibiotic therapy owing to their unique 
physicochemical properties. These include their small size, large ratio of surface area to mass, and 
unique interactions with microorganisms and cells of the host, in addition to their capability to be 
structurally and functionally modified (Kalhapure et al., 2014c; Zhang et al., 2007; Zhang et al., 
2010). Examples of such systems are silver nanoparticles (Kalhapure et al., 2014a; Mala et al., 
2012; Morones et al., 2005), solid lipid nanoparticles (Kalhapure et al., 2014b; Wang et al., 2012; 
Xie et al., 2011), liposomes (Drulis-Kawa et al., 2006; Pumerantz et al., 2011; Sande et al., 2012) 
and even the synthesis of new antimicrobial materials, such as  dendrimers (Cheng et al., 2007; 
Felczak et al., 2013; Svenson, 2009) and antimicrobial peptides (Faccone et al., 2014).  
Polymeric materials, which comprise natural, seminatural and synthetic polymers, propose endless 
opportunities to control the properties of drug delivery systems besides meeting numerous criteria 
such as biocompatibility, biodegradability and reproducibility, due to their diversity in topology, 
chemistry and dimension. Several types of polymeric materials, for instance linear polymers (Qiu 
and Bae, 2006), block copolymers (Kumar et al., 2001; Qiu and Bae, 2006) and hyperbranched 
polymers (Gao and Yan, 2004; Jikei and Kakimoto, 2001), are being studied for drug delivery 
systems. In this study, dendrimers (Gillies and Frechet, 2005; Huh and Kwon, 2011; Inoue, 2000; 
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Qiu and Bae, 2006) and star polymers (Gao, 2012; Inoue, 2000; Qiu and Bae, 2006) were 
specifically addressed.  
Silver, which is a powerful antimicrobial agent, mainly in its positively charged ionic form, 
demonstrates good toxicity to an extensive range of micro-organisms, and simultaneously has a 
principally low human toxicity (Dallas et al., 2011; Gibbins and Warner, 2005; Liau et al., 1997). 
Additionally, it is able to interrupt significant functions in a microorganism that causes AMR. 
Nevertheless, it is imperative to be mindful of the fact that silver is only non-toxic to human cells 
in small concentrations (Pal et al., 2007), and thus restricts the use of metallic silver and silver ions 
as antibacterial agents up to concentrations that are non-toxic to eukaryotic cells. Dendrimers, 
instead are repetitively branched molecules or nano-sized, radially symmetric molecules, having 
well-defined, uniform and monodisperse structures, and comprise of branches that surround a core 
(Bosman et al., 1999; Hari et al., 2012). They are a great source for finding novel and distinct 
properties due to their accessibility of numerous functional surface groups and low polydispersity 
(Hari et al., 2012; Inoue, 2000).  
Owing to their unique properties, and because they can be modified to therapeutic needs, they have 
become model carriers for small molecule drugs and biomolecules (Svenson, 2009). They have 
also gained added attention as possible antimicrobial agents due to the availability of numerous 
end groups and compressed structure (Chen and Cooper, 2000; Polcyn et al., 2013). Commonly, 
dendrimers display promising biocompatibility (Svenson, 2009), which is vital for their 
application, and can be used as antimicrobial agents themselves (Charles et al., 2012; Chen et al., 
2000; Felczak et al., 2012; Lopez et al., 2009). Poly propylene imine (PPI), polylysine, triazine 
(Jain et al., 2010) and polyamidoamine (PAMAM) are the most widely used dendrimers in drug 
delivery, with PAMAM being the first and most frequently studied (Svenson, 2009). However, its 
advantages are constricted by  limitations such as cytotoxicity, which is caused by its amine-
terminated nature (Sosnik et al., 2010) and there are consequently no commercially available 
dendrimer based preparations for systemic use (Jain et al., 2010). Conversely, poly (propyl ether 
imine) (PETIM) dendrimers, a relatively new class of dendrimers, have been described to have 
good biocompatibility compared to commercial PAMAM dendrimers.  
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While they have numerous advantages, such as non-cytotoxicity and easy functional group 
modification at the periphery, their potential for antimicrobial therapy is yet to be exploited. While 
the potential to develop complexes of silver and dendrimers to enhance antimicrobial activity has 
been demonstrated,  but research is limited (Balogh et al., 2001; Ottaviani et al., 2002). Balogh et 
al. and Ottaviani et al. are the very few reported papers who prepared poly(amidoamine) 
(PAMAM) dendrimer based silver complexes. To the best of our knowledge, no other classes of 
dendrimers have been used to prepare silver salts, highlighting the need for further studies on 
dendrimer silver salts.  
Numerous types of metal nanomaterials have been studied to date (Esumi et al., 2000; Gong et al., 
2007; Huang et al., 2008), yet silver nanoparticles are at the forefront of research, being the most 
effective due to their exceptional antimicrobial efficacy against not just bacteria, but viruses and 
other eukaryotic micro-organisms as well (Gong et al., 2007; Rai et al., 2009). Silver nanoparticles 
appear to be a more suitable choice when compared to the silver cation salts and complexes. 
Moreover, when compared to commercially available antibiotics that can cause harm to valuable 
enzymes, colloidal silver allows these enzymes to remain unharmed (Dallas et al., 2011).  
Bacterial resistance has also yet to be identified when using silver nanoparticles as antibacterial 
agents. This is apparently a consequence of the difference mechanisms of the antibacterial actions 
of the various forms of silver (Gogoi et al., 2006; Kvitek et al., 2008; Yamanaka et al., 2005). An 
important application problem associated with silver nanoparticles is the sufficient stability of their 
dispersions and the prevention of aggregation (Shrivastava et al., 2007; Teeguarden et al., 2007). 
To combat this problem, various polymers are often used to stabilise these metal colloids, as 
polymers act as a type of matrix, and have been commonly used for trapping nanoparticles (Jeon 
et al., 2008; Lu et al., 2006; Spadaro et al., 2010). Numerous methods have also been established 
to immobilise silver nanoparticles in the polymeric matrix. Among those techniques, chemical 
reduction is the most regularly utilised approach, which consists of adding a reducing agent, such 
as sodium borohydride (NaH4), sodium citrate (Na3C6H5O7), ascorbate or lithium aluminium 
hydride (LiAlH4), to reduce silver nitrate (AgNO3) in an aqueous solution (Huang et al., 2012; Lu 
et al., 2006; Wang et al., 2010).  
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Star polymers are the simplest type of branched materials in which no less than three linear 
polymer chains, with basically identical lengths, are linked to only one branching point (core) 
(Inoue, 2000; Kuzuu, 1980; Wu et al., 2015). They can contain chemically identical or different 
arms (miktoarm star polymer) that are linked to the core, and have gained interest due to their 
distinctive topological structure and attractive physical and chemical properties, which are unlike 
their linear counterparts (Jia et al., 2014; Wu et al., 2015). Furthermore, they contain a greater 
degree of end group functionalities that are essential in specific applications (Wang et al., 2005). 
Hence, if the components of the star polymers are biodegradable and/or biocompatible, they can 
have various possible biomedical applications (Jia et al., 2014; Wu et al., 2015). These star 
polymers could be regarded as a new family of stabilising agent for  preparing colloidal silver 
nanoparticles, as very few star polymers have been utilised as stabilising agents thus far (Huang et 
al., 2012; Sun et al., 2010; Zhang et al., 2008). Therefore, the search for new polymers as 
stabilising agents is of great importance to facilitate their application as antimicrobials. There is 
thus a gap with regards to not only dendrimer silver salts, but also stabilising agents for silver 
nanoparticles.  
1.3 Aims and objectives  
The aim of the study was to: (1) explore the potential of novel antimicrobial dendrimer silver salts 
for enhanced antimicrobial activity and (2) explore the potential of a novel star shaped polymer 
for use as a stabilising agent in the preparation of silver nanoparticles. 
In order to accomplish the first aim, the objectives of the study were to: 
1. Design and synthesise novel PETIM silver salts of generation 1 poly (G1) (propyl ether
imine) (PETIM) dendron and dendrimers.
2. Characterise the synthesised PETIM dendron/dendrimers and PETIM silver salts in terms
of infrared spectroscopy (IR) and/or nuclear magnetic resonance spectroscopy (NMR).
3. Evaluate the cytotoxic effects of the PETIM silver salts in terms of MTT assay.
4. Assess the potential of the prepared samples as antimicrobial agents by in vitro
antimicrobial testing.
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To accomplish the second component of the aim, the objectives were to: 
5. Design and synthesise a biocompatible and biodegradable G1 PETIM-m-PEG star shaped
polymer.
6. Characterise the synthesised polymer in terms of IR, 1H NMR, 13C NMR, and X-ray
diffraction (XRD) analysis.
7. Evaluate the cytotoxic effects of the star shaped polymer in terms of MTT assay.
8. Prepare star polymer stabilised silver nanoparticles and determine their particle size,
polydispersity index (PDI), morphology and stability.
9. Evaluate the cytotoxic effects of the star polymer stabilised silver nanoparticles in terms
of MTT assay.
10. Assess the potential of the prepared samples as antimicrobial agents by in vitro
antimicrobial testing.
1.4 Novelty of this study 
Dendrimers, dendritic polymers and star polymers, due to their uniqueness, are a promising new 
scaffold for drug delivery. Numerous branched polymers have been developed worldwide, and the 
synthesis of these polymers are ongoing. However, the dendritic materials reported in this study 
are novel for various reasons:  
 While other classes of dendrimers, such as PAMAM, have been extensively used and
studied, data on PETIM dendrimers is lacking. Although the latter have several advantages,
such as non-cytotoxicity and easy functional group modification at the periphery, their
potential for antimicrobial therapy has not been exploited. This study is therefore the first
combination of PETIM dendrimers and silver to identify novel antimicrobial materials
effective against both sensitive and resistant bacterial strains.
 While several studies have been reported on the synthesis and characterisation of star
polymers, as well as the application of certain hyperbranched and star polymers as
stabilising agents, to our knowledge, there are no studies on the use of a novel PETIM-m-
PEG type of star polymer as a stabilising agent in silver nanoparticles production. The PEG
six-arm star-shaped polymer synthesised in this study has not been reported previously.
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1.5 Significance of this study 
The formation of new polymeric materials for application in antimicrobial systems offers a novel 
and promising means of overcoming the resistance that is associated with most the frequently used 
antibiotics. The potential benefits of formulating the novel polymeric materials proposed in this 
study may include the following: 
 With the rise in AMR and the lack of commercially available superior polymeric materials
to overcome the ever threatening complications which arise from resistance, identifying
new polymeric materials for applicability in developing novel nano-delivery systems could
be of great value to combating this global problem.
 The development of these novel materials could mean cost-effective and superior delivery
systems may be developed, and could not only lead to a reduction in health care costs
worldwide, but also improvements in  infectious diseases treatment and management.
 These new materials with antimicrobial properties will widen the pool of available
materials for formulation scientists to explore for additional applications.
 New knowledge on the applicability and antimicrobial properties of PETIM
dendron/dendrimers, as well as the applicability of star polymers as stabilising agents for
nanoparticle formation, could be obtained.
1.6 Overview of this thesis 
The study will be presented in the following five chapters: 
Chapter 2. Literature Review: reviews infectious diseases, the resistance associated with these 
diseases and strategies to overcome their current limitations. This chapter focuses on the 
synthesis of novel polymeric material and their use as antimicrobial agents. Additionally, 
various types of polymeric materials are described, with particular focus on dendrimers and 
star polymers and their role in medicine. 
Chapter 3. (publication) is a first author article accepted in an ISI international journal. This 
chapter is presented in the mandatory format of the journal and is the final revised accepted 
version. It reports on novel work published in an international journal. It describes the 
synthesis of biocompatible PETIM silver salts as novel antimicrobial agents. 
Chapter 4. (manuscript) is a first author manuscript submitted to an ISI international journal. This 
chapter is presented in the mandatory format of the journal and is the final version submitted 
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for review. It describes the synthesis of a novel biocompatible star polymer and its use as a 
stabilising agent in the preparation of silver nanoparticles.  
Chapter 5. (publication) is a co-authored review article reporting on nanoengineered drug delivery 
systems for enhancing antibiotic therapy. 
Chapter 6. Conclusion: addressed the study aim with respect to the seven objectives, outlines the 
limitations, the significance of the findings, and provides recommendations for future studies 
to widen the use of silver salts as antimicrobial agents, and to optimise the use of star polymer 
stabilised silver nanoparticles as an ideal delivery system. 
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CHAPTER 2. INFECTIOUS DISEASES AND NOVEL POLYMERIC 
MATERIALS FOR DRUG DELIVERY 
 
2.1 Introduction 
This chapter encompasses a review of the literature on infectious diseases, the resistance associated 
with these diseases and the strategies to overcome their current limitations. It also focuses on the 
synthesis of novel polymeric material and their use as antimicrobial agents. Additionally, various 
types of polymeric materials are described, with particular focus on dendrimers and star polymers 
and their role in medicine. Finally, the use of silver as a model antimicrobial agent for this study 
is explained. 
 
2.2 Current status of infectious diseases and bacterial resistance 
Infectious diseases are disorders that result from the presence of a pathogenic agent, being either 
a virus, bacterium, fungus or parasite. These diseases are also known as communicable diseases 
due of their ability to be transmitted from one person to another (malaria, tuberculosis) and even 
occasionally from one species to another (flu, influenza) (Salouti and Ahangari, 2014). Infectious 
diseases, a significant portion of which are of bacterial origin, are one of the leading causes of 
untimely death globally for adults and children, and remain a major public health issue for 
developed and developing countries (Lozano et al., 2013). Africa, and South Africa in particular, 
have a high burden of infectious diseases and due to this, gastrointestinal, respiratory, sexually 
transmitted, and hospital acquired infections are leading causes of death in the developing world 
(Kalhapure et al., 2014; Winters and Gelband, 2011). While antibiotics revolutionised the 
treatment of infections, thereby extending the lives of millions of people, eighty years after their 
discovery, their effectiveness is seriously threatened by antimicrobial resistance (AMR) (Figure 1) 
(Cars et al., 2011). This nullifies the use of even the most potent antibiotics, which leads to patient 
suffering and/or dying due to poor infection control failure, and results in escalated health care 
costs (Huh and Kwon, 2011).  






Figure 1. Date of discovery and resistance of antibiotics. Adapted from Huh and Kwon, 2011 and 
Brooks and Brooks, 2014. 
 
Globally, resistant bacterial strains, such as methicillin-resistant Staphylococcus aureus (MRSA) 
(Cohen, 2000), vancomycin-resistant Enterococcus (VRE) (Wood et al., 1996) and vancomycin-
resistant Staphylococcus aureus (VRSA), (Périchon and Courvalin, 2009) have become significant 
threats in community settings and hospitals for treating infections. Additionally, emerging and re-
emerging infectious diseases (Huh and Kwon, 2011), together with concerns such as the rising 
global trade, international travel and the likelihood of bioterrorist attacks in numerous countries, 
have compounded the seriousness of infectious diseases (Kalhapure et al., 2014). If the current 
escalating trends in AMR continue, several important procedures, such as cancer chemotherapy, 
organ transplantation and hip and other joint replacements, could no longer be performed for fear 
that the related compromised immune system might put the patients at severe risk of acquiring a 
difficult to treat and ultimately fatal infection (Heymann and Rodier, 2001). The global AMR crisis 
is amplified by the decreasing development of new antibiotics by pharmaceutical companies (Cars 
et al., 2008), with 20 novel classes of antibiotics being developed in between 1930-1962 (Coates 
et al., 2002; Powers, 2004), yet only two novel classes have been developed  since then (Cars et 
al., 2008). This decline in drug development is due to the high costs and lengthy delays associated 
with developing a new chemical entity, high attrition rates at final testing, and increasing AMR, 
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Kwon, 2011; Okeke et al., 2005). It is therefore essential that alternative novel antimicrobial 
therapeutic strategies are explored to address the imminent crisis with conventional antibiotics. 
2.3 Current antibiotic therapy and limitations 
Antibiotic use began when penicillin was developed more than 70 years ago, their use being 
increasingly effective when newer, superior antibiotics were introduced to treat a host of infectious 
diseases, thereby contributing to lessening the related morbidity and mortality (Huh and Kwon, 
2011; Kalhapure et al., 2014). Antibiotics are considered essential in nearly all medical areas, such 
as general surgery, including organ transplant procedures, treatment of premature babies, and even 
chemotherapy in cancer patients cannot be accomplished without effectively treating and 
preventing bacterial infections (Cars et al., 2011).  
Unfortunately, there are several restrictions related to current antibiotic drug therapies. Various 
antibiotic dosage forms are compromised by inadequate drug concentrations at target infection 
sites, increased frequency of administration, severe side effects, and poor patient compliance, all 
of which inadvertently compromise drug therapy (Huh and Kwon, 2011; Sharma et al., 2012). 
These limitations, in addition to the common use and abuse of antibiotics, have contributed to their 
greatest drawback, i.e. resistance to bacterial microorganisms. Furthermore, the antibiotic 
resistance crisis has been intensified by pan drug-resistant and extensively drug-resistant 
organisms to antibiotics, which has reached distressing levels worldwide (Cars et al., 2011; Seil 
and Webster, 2012). Although new methods to overcome antibiotic resistance are constantly being 
researched and developed, antibiotic discovery is not on par with the rates of drug resistance, and 
a gradual and steady decrease in the introduction of novel drugs has been reported by the US Food 
and Drug Administration (FDA) (Brooks and Brooks, 2014; Taubes, 2008). This is due to the 
exorbitant costs and prolonged times for ultimate regulatory approval of new compounds, along 
with low returns on investment, which further compounds the current crisis (Kalhapure et al., 
2014; Sondi and Salopek-Sondi, 2004). It is therefore evident that the pace at which drug 
development and registration is going is not timeously receptive to the hasty development of 
resistance by microbial pathogens.  





This rising development of antibiotic resistance to presently used antibiotics, and the decline in 
introduction of new antibiotic drugs, is unmistakably a risk to human health worldwide (Kalhapure 
et al., 2014). The quest for novel and effective approaches to enhance drug therapy with existing 
antibiotics is therefore identified globally as a key focus area of research priority (Kalhapure et al., 
2014), and combatting this multifaceted issue of antibiotic resistance must go past the development 
of novel pharmaceuticals and include a multidisciplinary culture of change (Brooks and Brooks, 
2014). 
 
2.4 The use of nanotechnology to overcome limitations with current antibiotic drugs 
The vital components to combat the continued expanding threat of AMR include various 
approaches such as: establishing an effective surveillance system for early detection of AMR; 
methods to optimise the use of antibiotics; resilient infection control and prevention methods to 
avoid the spread of AMR; improvements in healthcare providers and public education, and 
alertness concerning antibiotics to avoid their incorrect use; as well as research to guide the 
aforementioned points and to develop novel antibiotics that offer effective treatment to patients 
(Paphitou, 2013). While there is general agreement that a multifaceted strategy is essential to 
address the problem, little is known about which approach will be effective and economical to 
accomplish this goal (Paphitou, 2013). 
 
Conversely, the use of nanotechnology for drug delivery is widely anticipated to alter the landscape 
of the pharmaceutical and biotechnology industries in the upcoming years (Farokhzad and Langer, 
2009). The noteworthy advantages of using nanotechnology for treating numerous illnesses by 
improving the solubility, efficacy, bioavailability, and specificity of drugs are extensively 
acknowledged in the literature (Kalhapure et al., 2014). Nanotechnology refers to the design, 
production, and application of nanosized materials, and is considered to be a new paradigm to 
enhance the outcomes in infectious diseases treatment (Huh and Kwon, 2011). New nanosized 
drug delivery systems might be a favourable approach to overcome the existing challenges related 
to antibiotic therapy due to their unique physicochemical properties (Figure 2). 





   
 
Figure 2. Development of resistance with conventional dosage forms and the mechanisms used to 
overcome resistance using nano delivery systems. 
 
These include their small size, large ratio of surface area to mass, and unique interactions with 
microorganisms and cells of the host, in addition to their capability to be structurally and 
functionally modified (Kalhapure et al., 2014; Zhang et al., 2007; Zhang et al., 2010).  These 
systems offer various advantages, such as targeted delivery to the infection site, fairly even 
distribution in the identified tissue, better cellular bacterial internalisation and solubility, sustained 
drug release, and improved patient compliance, thereby increasing the efficiency and efficacy of 
therapy, and concurrently reducing side effects (Mansour et al., 2009; Salouti and Ahangari, 2014; 
Sosnik et al., 2010). Figure 2 represents the characteristics of an optimal nanocarrier. 






Figure 3. The characteristics of an ideal nanocarrier. Adapted from Abed and Couvreur, 2014.  
 
More notably, inherent mechanisms to overcome resistance include: photocatalytically 
manufacturing reactive oxygen species (ROS), which harm cellular and viral constituents, 
compromising of the bacterial cell wall/membrane, disrupting energy transduction, and inhibiting 
enzyme action and DNA synthesis (Figure 4) (Huang et al., 2008; Huh and Kwon, 2011; Kim et 
al., 2007; Li et al., 2008; Maness et al., 1999; Pal et al., 2007; Rabea et al., 2003; Weir et al., 
2008). 
 





Figure 4. Various antimicrobial mechanisms of nanomaterials. Adapted from Huh and Kwon, 
2011, and Brooks and Brooks, 2014.  
 
The utilisation of nanosystems as delivery vehicles for antimicrobial agents proposes a novel and 
promising model in designing effective therapeutics against numerous pathogenic microbes 
(Salouti and Ahangari, 2014), as these systems have been found to overcome prevailing specific 
drug-resistance mechanisms by microorganisms (Pelgrift and Friedman, 2013).  Moreover, 
combining a few antibiotics into these nanosystems, which are capable of overcoming resistance 
mechanisms and having antimicrobial activity, can encourage synergistic activities and resistance 
overcoming effects (Zhang et al., 2010). These benefits are documented as the main contributors 
to incapacitating bacterial resistance related to poor delivery of antibiotics (Blecher et al., 2011). 
Nanodrug delivery systems thus propose an innovative and superior method to overcoming 
numerous limitations linked to the currently available antibiotic drug therapies, including the 
severe worldwide threat of antibiotic resistance (Table 1). However, when compared to cancer and 
cardiovascular disease conditions, the use of nanodrug delivery systems for specifically 
encapsulating and distributing antibiotic drugs is still in early stages (Huh and Kwon, 2011).  
 
  





Table 1. The advantages and disadvantages of antimicrobial nanoparticles over free antimicrobial 
agents. Adapted from Huh and Kwon, 2011.  
Antimicrobial nanoparticles Free antimicrobial agents 
Advantages Disadvantages 
Targeted drug delivery by specific accumulation No specific accumulation 
Lower chance of antimicrobial resistance Higher chance of antimicrobial resistance 
Less side effects of chemical antimicrobials More side effects of chemical antimicrobials 
Extended therapeutic lifetime owing to slow elimination Shorter half-life owing to quick elimination  
Controlled drug release The usual pharmacokinetic properties of free drugs 
Enhanced solubility At times poor solubility  
Wide-ranging therapeutic index Narrow therapeutic index 
Cost effective Costly 
Low immunosuppression Immunosuppression  
Disadvantages Advantages 
The accumulation of intravenously injected nanomaterials in 
tissues and organs 
Complete absence of nanomaterials in the entire 
body 
A high systemic contact to locally administered drugs A low systemic contact to locally administered drugs 
Nanotoxicity in the brain, kidneys, lungs, liver, metabolism, germ 
cells, etc. 
The nonexistence of nanotoxicity  
The deficiency of characterisation methods that are not affected by 
nanoparticles’ properties  
Well-established characterisation methods  
 
2.5 Types of polymeric materials for nano-drug delivery 
The use of formulation materials such as lipids and polymers are essential for the formulation of 
nanosystems. When compared to other classes of materials, polymeric materials, which include 
natural, seminatural, and synthetic polymers, offer limitless opportunities to control the properties 
of drug delivery systems properties, other than to meet numerous criteria, such as biocompatibility, 
biodegradability and reproducibility, due to their diversity in topology, chemistry and dimension. 
Different types of polymeric materials are continually being studied for drug delivery systems and 
include block copolymers (Kumar et al., 2001; Qiu and Bae, 2006), dendrimers (Gillies and 
Frechet, 2005; Huh and Kwon, 2011; Inoue, 2000; Qiu and Bae, 2006), hyperbranched polymers 
(Chen et al., 2008; Inoue, 2000; Qiu and Bae, 2006), as well as star polymers (Gao, 2012; Inoue, 
2000; Qiu and Bae, 2006).  
 
2.5.1 Block copolymers 
Block copolymers can be defined as polymers with two or more blocks or segments assembling in 
the main chain (Figure 5), being categorised according to their architecture as AB-type diblock, 





ABA- or BAB-type triblock, and multiblock, where A denotes the soluble block in a particular 
solvent and B designates the insoluble block (Kumar et al., 2001; Qiu and Bae, 2006). They have 
the ability to manipulate their amphiphilic behaviour, as well as their mechanical and physical 
properties by modifying the ratio of the constituting block, or by adding new blocks of preferred 
properties (Kumar et al., 2001). 
 
                                       
Figure 5. Block copolymer. Adapted from Qiu and Bae, 2006.  
 
Block copolymers in particular have gained considerable attention, not just due to the scale of their 
microdomains (tens of nanometres) and their numerous chemical and physical properties, but also 
because of their appropriate size and shape tunability of their microdomains attained by simply 
varying their molecular weights and compositions (Park et al., 2003). Widespread work has been 
carried out over the last few decades, to synthesise block copolymers for drug delivery in 
nanoparticles, hydrogels, implants, micelles etc. (Kumar et al., 2001). A method to attain these 
copolymers that allows surface modification is attaching polyethylene glycol (PEG) chains to a 
biodegradable polymer, such as poly(lactic acid) (PLA) or poly(lactide-co-glycolic acid) (PLGA). 
Although several possible uses of block copolymers for different nanotechnologies have been 
suggested, based primarily on their capability to form interesting patterns, the foremost challenge 
of using these polymers is with controlling their microstructure (Park et al., 2003). 
 
2.5.2 Dendrimers  
Dendrimers are repeatedly branched molecules or nano-sized, radially symmetric molecules that 
have a well-defined, uniform and monodisperse structure that consists of branches surrounding a 
core (Figure 6) (Bosman et al., 1999; Hari et al., 2012).  






Figure 6. Dendrimer. Adapted from Qiu and Bae, 2006. 
 
The availability of several functional surface groups, and their low polydispersity, make them a 
rich source for finding novel and unique properties (Hari et al., 2012; Inoue, 2000). Due to these 
very distinctive properties, and the fact that they can be adapted to therapeutic needs, they are 
regarded as good carriers for small molecule drugs and biomolecules (Svenson, 2009). Dendrimers 
have gained further interest as likely antimicrobial agents due to the availability of numerous end 
groups and their compressed structure (Chen and Cooper, 2000; Polcyn et al., 2013). Therefore, if 
any one of the functional groups is capable of interacting with a target, other groups within close 
proximity of one another could make synergistic interactions for antimicrobial activity possible 
(Chen and Cooper, 2000). Specific interactions (e.g. quaternary ammonium based dendrimers) aim 
to eliminate bacterial/viral infections by inhibiting the growth of microbes, thereby killing them 
and nonspecific interactions (e.g. oligosaccharide based dendrimers), and preventing the initial 
attachment between bacteria/viruses and host cells (Chen and Cooper, 2000). 
 
It has also been highlighted that dendrimers show promising biocompatibility in general (Svenson, 
2009), which is essential for their application, and can therefore be used as antimicrobial agents 
(Charles et al., 2012; Chen et al., 2000; Felczak et al., 2012; Lopez et al., 2009). Consequently, 
highly potent dendrimer based antibacterial agents have been synthesised (Charles et al., 2012; 
Chen et al., 2000). Currently, the dendrimers most extensively used for drug delivery include poly 
propylene imine (PPI), polylysine, triazine (Jain et al., 2010) and polyamidoamine (PAMAM), the 





latter being the first and most commonly studied (Svenson, 2009). Unfortunately, its uses are 
constrained by limitations such as cytotoxicity, which results from its amine-terminated nature 
(Sosnik et al., 2010), and as a result, there are no commercially available dendrimer based 
formulations for systemic administration (Jain et al., 2010). Conversely, hand carboxylic- or 
hydroxyl-terminated PAMAM dendrimers, which seem to be more biocompatible and less toxic 
than unmodified ones, can be simply conjugated with antimicrobial agents through abundant 
functional groups (Gillies and Frechet, 2005; Sosnik et al., 2010). Numerous other antimicrobial 
drugs have been successfully combined into dendrimer nanoparticles for better solubility and, thus, 
therapeutic efficacy (Table 2). 
 




































A high payload and lengthy 
circulation half-life 
(Suri et al., 
2007) 
PLCP Artemether Plasmodium 
falciparum 
Increased drug stability, improved 
solubility and lengthy drug 
circulation half-life. 
(Bhadra et al., 
2005) 
PAMAM Sulfamethoxazole Escherichia coli Sustained drug release, improved 
antibacterial activity by enhanced 
penetration of antibiotics through 
the bacterial membrane, aided by 
surface amine groups at a high 
density. 
(Ma et al., 
2007) 
PAMAM Nadifloxacin and 
Prulifloxacin 
Escherichia coli Enhanced water solubility with 
strong antimicrobial activity by 
greater penetration of antibiotics 
through the bacterial membrane. 
(Cheng et al., 
2007) 
 
A relatively new class of dendrimers, known as the poly (propyl ether imine) (PETIM) dendrimers, 
has been reported to have good biocompatibility when compared to commercial PAMAM 
dendrimers, and has been effectively applied for encapsulating ketoprofen for sustained drug 
delivery. (Jain et al., 2010) Although it has several advantages, such as non-cytotoxicity and easy 
functional group modification at the periphery, its potential for antimicrobial therapy has not been 
exploited.  
 





2.5.3 Hyperbranched and Star polymers       
Hyperbranched polymers are highly branched macromolecules with a three-dimensional dendritic 
structure (Figure 7), and have gained growing attention due to their unique properties, relative ease 
of preparation and greater availability compared to dendrimers (Gao and Yan, 2004; Jikei and 
Kakimoto, 2001). Their structure is not as controlled as that of dendrimers, and their functional 
groups are not situated at an ordered position. Therefore, the degree of branching for dendrimers 
and hyperbranched polymer is quite different, although their overall compositions are similar. 
Thus, hyperbranched polymers may have intermediate properties between that of linear and 
dendritic polymers (Inoue, 2000). These biocompatible polymers display low toxicity and can be 
considered as candidates for drug delivery (Paleos et al., 2010). As polymers act as a kind of 
matrix, they have been extensively utilised for trapping nanoparticles (Jeon et al., 2008; Lu et al., 
2006; Spadaro et al., 2010), with various hyperbranched polymers having been reported to have 
been used as stabilising agents for metal nanoparticles (Aymonier et al., 2002; Zhang et al., 2008). 
 
Figure 7. Hyperbranched polymer. Adapted from Qiu and Bae, 2006. 
 
Star polymers are known as the simplest type of branched materials, wherein at least three linear 
polymer chains with essentially identical lengths are attached to only one branching point (core) 
(Figure 8) (Inoue, 2000; Kuzuu, 1980; Wu et al., 2015). These polymers can contain chemically 





identical or different arms (miktoarm star polymer) linked to the core. 
 
Figure 8. Star polymer. Adapted from Qiu and Bae, 2006. 
 
Various methods have been applied to synthesise star polymers (Inoue, 2000), and have attracted 
considerable attention due to their unique topological structure, and the fact that their attractive 
physical and chemical properties are different from their linear counterparts (Jia et al., 2014; Wu 
et al., 2015). Usually, star polymers have a smaller hydrodynamic dimension, reduced solution 
and lower melt viscosities than their linear counterparts with equivalent molecular weights (Deng 
and Chen, 2004; Sun et al., 2010). Moreover, they also have a higher degree of end group 
functionalities that are fairly important in specialised applications (Wang et al., 2005b). Therefore, 
if the components of the star polymers are biodegradable or biocompatible, these copolymers can 
have potential biomedical applications, such as drug/gene delivery, tissue engineering, diagnosis, 
medical devices, and antibacterial/antifouling biomaterials (Jia et al., 2014; Wu et al., 2015).  
 
Star polymers also display promising performance in sustained, controlled and targeted drug 
delivery, and have been extensively applied to improve drug delivery systems. Dendritic polymers 
are associated with the usual peripheral drug conjugation and loose internal drug loading space, 
while star polymers provide other internal drug-conjugated sites and looser drug loading space 
(She et al., 2013; Wu et al., 2015; Zhang et al., 2014; Zhou et al., 2014). Owing to exceptional 
drug loading capacity and controllable properties of star polymers, many researchers are currently 
using the latter for in vivo drug delivery studies. For example, a class of unimolecular nanocarriers 
based on star polymers has been explored to control drug release (Jones et al., 2003; Lee et al., 





2011; Li et al., 2012; Wu et al., 2015). Star polymers could be a novel family of stabilising agent 
to prepare colloidal silver nanoparticles. Although an amphiphilic modified hyperbranched 
polyethyleneimine polymer has been used to stabilise silver nanoparticles and displayed certain 
attractive advantages, for instance, the quasi-spherical branched assembly with numerous inner 
cavities and nearly nonexistence of chain entanglements (Aymonier et al., 2002), very few star 
polymers, particularly those that are water-soluble, have been utilised as stabilising agents so far 
(Huang et al., 2012; Sun et al., 2010; Zhang et al., 2008). Finally, although PEG/dendrimer star 
polymers have been synthesised and applied previously (Hedden and Bauer, 2003; Yang and 
Lopina, 2003), according to our knowledge, they are yet to be utilised as stabilising agents to 
prepare metal nanoparticles. 
 
2.6 G1 PETIM silver salts as antimicrobial agents 
A comprehensive literature search indicated a broad array of metal complexes being investigated 
and various types of silver complexes being studied, with few studies on dendrimer-silver salts 
being noted. A knowledge gap remains despite researchers having recognised the potential of 
developing complexes of silver and dendrimers to enhance antimicrobial activity, with Balogh et 
al. having prepared PAMAM dendrimer based silver complexes (Balogh et al., 2001), which 
showed enhanced antimicrobial effect, creating a new and potent antimicrobial agent for 
biomedical applications. The preparation of silver nanoparticles and silver nanocomposites are 
much more widely reported on compared to silver salts, and to the best of the researcher’s 
knowledge, there are only two published papers thus far on dendrimer-silver salts (Balogh et al., 
2001; Ottaviani et al., 2002). An overview of silver salts are presented in the following section. 
 
2.6.1 Preparation of silver salts 
A wide range of medicinal applications for metal complexes has been investigated with varying 
methods of preparation. To the researchers’ knowledge, no review article was found that discusses 
the preparation of silver salts. Two methods discussing metal complexes and two discussing silver 
salts have therefore been explained hereunder.  
For the first method, according to Creaven et al., Cu(hnc)2(H2O)2] 2H2O and [Ag(hnc)] complexes 
of hydroxynitrocoumarins were prepared in aqueous solution by deprotonating the hydroxyl group 
of 4-hydroxy-3-nitro-2H-chromen-2-one (hncH) with sodium hydroxide and then adding 





copper(II) chloride dihydrate and silver(I) nitrate, respectively. [Ag(hmnc)] was synthesised in a 
similar manner, the mixed-ligand Ag(I) complex [Ag-(phen)2hnc] was prepared by treating 
silver(I) nitrate with phen and a subsequent reaction with a solution containing hncH and sodium 
hydroxide (Creaven et al., 2005). Kleyi et al. prepared a solution of silver nitrate in ethanol, and 
2-hydroxymethyl-N-alkylimidazole was then added. The reaction was stirred at room temperature 
for 24 hours and was then filtered. Ethyl acetate was added and the solvent evaporated slowly at 
atmospheric pressure to obtain silver complexes containing ligands (Kleyi et al., 2012).  
 
For the second method, silver dendrimer complexes were synthesised by Ottaviani et al. They 
explained that individual dendrimers formed complexes with an equal and well-defined number of 
metal atoms per dendrimer molecule, which were expressed as average numbers. 5 ml of silver 
nitrate stock solution was added dropwise with stirring to a weighed amount of PAMAM 
dendrimer stock solution in methanol. The volumetric flask was filled up to 10.00 mL with 
methanol, resulting in a solution of sample containing nitrogen ligands silver ions for the 
investigated solutions. The metal ion/dendrimer ratio was predetermined by the ratio of metal ion 
moles per dendrimer moles due to the uniformity of dendrimers and the isotropic nature of the 
diffusion (Ottaviani et al., 2002). Balogh et al. prepared silver containing PAMAM complexes by 
adding aqueous solutions of the dendrimers to the calculated amount of silver acetate powder. 
Although silver acetate is poorly soluble in water, it dissolved rapidly in PAMAM solutions. This 
was due to the combined action of the silver-carboxylate formation and/or to the complex 
formation with the internal nitrogens. The procedure resulted in slightly yellow dendrimer-
complex/salt solutions (Balogh et al., 2001). 
 
2.6.2 Characterisation of silver salts 
As mentioned above, as no review articles was found discussing silver salts, a few characterisation 
methods of metal complexes and silver salts are briefly discussed. Infrared spectra is most often 
used to characterise silver salts. Salts of carboxylic acids do not display any of the carbonyl bands 
rather bands owing to the asymmetric and symmetric stretching vibrations of the equivalent 
carbon-oxygen bonds. They are observed at 1610-1550 cm-1 and 1420-1300 cm-1 respectively, 
which provides evidence for the carboxylate anion (Vogel and Furniss, 1989). Noteworthy changes 
in absorption frequencies reported by Creaven et al., between the free and coordinated ligands, 





were ν asym(NO2) stretch of the nitro group, the ν(C=O) and ν(C–O) stretches of the lactone (in 
hncH), and the phenoxy alcohol ν(O–H) stretch (in hmncH) (Creaven et al., 2005). Kleyi et al. also 
reported differences in spectra between their complexes and free ligands. The IR spectra of 
silver(I) complexes displayed bands in the 3500–3100 cm-1 region, showing the occurrence of –
OH functional groups. The occurrence of these bands also showed that the –OH groups were not 
contributing in the coordination to the metal centre. Imidazoles vibrational bands at 1450–1300 
cm-1 seem somewhat shifted to lower frequencies in the complexes compared to the free ligands, 
and the bands also seem to display a noticeable broadening. The shifting and broadening of these 
bands showed the coordination of the ligands through the C=N nitrogen atoms of imidazoles (Kleyi 
et al., 2012). 
 
Electron paramagnetic resonance (EPR) technique has been effectively applied previously (Balogh 
and Tomalia, 1998) to increase an understanding of the detailed assembly of copper(II) complexes 
of amine and methylester terminated PAMAM dendrimers. As these ions have been studied 
widely, they can be used as reporter ions. Computer-aided analysis of the EPR spectra offers 
information on the development of copper complexes in numerous internal or external locations 
of the dendrimers, together with the structure of the complexes and nanocomposites as a function 
of the size and surface of the dendrimers, temperature, silver content, etc. (Ottaviani et al., 2002). 
 
2.7 Overview of silver nanoparticles  
Noble metal nanoparticles have attracted attention due to their unique properties and potential 
applications in numerous areas, such as sensors, medicine, catalysts and electronics (Huang et al., 
2012; Jain et al., 2008; Wuithschick et al., 2015). Various kinds of metal nanomaterials have been 
studied to date, however, silver nanoparticles are shown as being most effective and promising in 
biomedical and pharmaceuticals (Rai et al., 2009). This can be ascribed to their good antimicrobial 
efficacy against not only bacteria, but also viruses and other eukaryotic micro-organisms (Gong et 
al., 2007; Rai et al., 2009). While elemental silver and silver salts have been recognised as 
antimicrobial agents in preventive and curative health care since ancient times (Dallas et al., 2011), 
their use could cause unwanted adsorption of ions in the sweat glands and epidermal cells (Dallas 
et al., 2011; Russell and Hugo, 1994; Silver and Phung, 2005). Hence, silver nanoparticles appear 
to be a better candidate compared to the silver cation salts and complexes (Dallas et al., 2011). 





Furthermore, the importance of silver nanoparticles, as promising antibacterials, lies in the fact 
that, unlike commercial antibiotics, they do not damage useful enzymes in the host (Dallas et al., 
2011). Silver nanoparticles have unique physical and chemical properties, and are considered an 
alternate for developing novel antibacterial agents. Furthermore, they have varied medical 
applications, such as coatings for medical devices, wound dressings and textile fabrics (Rai et al., 
2009). Bacterial resistance has also not yet been detected with the use of silver nanoparticles. This 
is apparently a result of the difference in the mechanism of the antibacterial actions of the diverse 
forms of silver (Gogoi et al., 2006; Kvitek et al., 2008; Yamanaka et al., 2005). It is extremely 
unlikely that resistance to antimicrobial silver might ever develop, as this would mean that an 
organism would have to undertake simultaneous mutations in every critical function within just a 
single generation to evade the compounds multiple actions (Gibbins and Warner, 2005). 
 
2.7.1 Silver nanoparticles as antimicrobial agents 
The use of silver to treat bacterial infections became unpopular due to the introduction of penicillin 
in the 1940s (Chopra, 2007; Huh and Kwon, 2011). However, the recent occurrence of antibiotics-
resistant bacteria, and the inadequate efficacy of antibiotics, resuscitated the clinical use of silver, 
for example in wound dressings (Huh and Kwon, 2011; Taubes, 2008). Various researchers have 
studied the bactericidal efficacy of silver nanoparticles, and their effective potential against a wide 









Table 3. Activity of silver nanoparticles against a wide spectrum of bacteria. Adapted from Rai et 
al., 2012.  
Form of silver Target organisms References 
Silver ions Escherichia coli and Staphylococcus aureus (Feng et al., 2000) 
Silver nitrate Periodontal pathogens (Spacciapoli et al., 2001) 
Silver zeolite Escherichia coli (Matsumura et al., 2003) 
Silver nanoparticles Escherichia coli (Pal et al., 2007; Sondi and 
Salopek-Sondi, 2004) 
Silver ions RNA viruses (Butkus et al., 2004) 
Silver nanoparticles Escherichia coli, Vibrio cholera, Salmonella typhus, and 
Pseudomonas aeruginosa 
(Morones et al., 2005) 
Silver nanoparticles Escherichia coli in liquid and solid medium (Baker et al., 2005) 
Silver ions Escherichia coli (Yamanaka et al., 2005) 
Silver nanoparticles Escherichia coli and Staphylococcus aureus (Shahverdi et al., 2007) 
Super paramagnetic silver 
nanoparticles, bifunctional 
Fe3O4, Ag nanoparticles 
Escherichia coli, Bacillus subtilis and Staphylococcus 
epidermis 
(Gong et al., 2007) 
Nanofiber impregnated silver 
nanoparticles 
Escherichia coli and Staphylococcus aureus (Jia et al., 2007) 
Silver nanoparticles on cotton 
fabrics 
Staphylococcus aureus (Durán et al., 2007) 
Silver nanoparticles 
impregnanted on wound 
dressings 
Escherichia coli and Staphylococcus aureus (Maneerung et al., 2008) 
Silver nanoparticles Escherichia coli, Salmonella typhi, Staphylococcus 
epidermis and Staphylococcus aureus 
(Ingle et al., 2008) 
Silver nanoparticles Phoma golmerata, Phoma herbarum, Fusarium 
semitectum, Trichoderma sp. and Candida albicans 
(Gajbhiye et al., 2009) 
Silver nanoparticles Escherichia coli, Staphylococcus aureus and 
Pseudomonas aeruginosa 
(Birla et al., 2009) 
Silver nanoparticles Escherichia coli and Staphylococcus aureus (Gade et al., 2010) 
Silver nanoparticles Escherichia coli and Pseudomonas aeruginosa (Geethalakshmi and 
Sarada, 2010) 
Silver nanoparticles Escherichia coli, Staphylococcus aureus and 
Pseudomonas aeruginosa 
(Bonde et al., 2012) 
Silver nanoparticles Pseudomonas aeruginosa, Staphylococcus aureus, 
pathogenic fungi Aspergillus flavus and Aspergillis 
niger  
(Govindaraju et al., 2010) 
Silver nanoparticles Escherichia coli, Staphylococcus aureus, Klebsiella 




Silver nanoparticle coated 
medical devices 
Staphylococcus aureus and Streptococcus mutans (Ki-Young, 2011) 
Bacterial cellulose-silver 
nanoparticle composite 
Escherichia coli and Staphylococcus aureus (Barud et al., 2011) 
 
In addition, silver nanoparticles display bactericidal potential against drug resistant bacteria (Rai 
et al., 2012). A review of the antimicrobial potential of silver nanoparticles against drug resistant 
bacteria is stated in Table 4.  






Table 4. The antimicrobial activity of silver nanoparticles against drug resistant bacteria. Adapted 
from Rai et al., 2012. 
Drug resistant bacteria References 
MRSA (Panáček et al., 2006) 
MRSA and non-MRSA (Ayala-Núñez et al., 2009) 
Streptococcus mutans (Espinosa-Cristóbal et al., 2009) 
MRSA, Methicillin sensitive Staphylococcus epidermis (MRSE) and Streptococcus 
pyogenes 
(Nanda and Saravanan, 2009) 
MRSA and MRSE (Saravanan and Nanda, 2010) 
Erythromycin-resistant Streptococcus pyogenes, Ampicillin-resistant Escherichia coli 
and multidrug-resistant Pseudomonas aeruginosa 
(Lara et al., 2010) 
Staphylococcus aureus, Methicillin sensitive S. aureus (MSSA) and MRSA (Ansari et al., 2011) 
 
The antimicrobial action of silver nanoparticles has an inverse relationship with shape (Pal et al., 
2007) and size (Raimondi et al., 2005; Sondi and Salopek-Sondi, 2004). The combination of silver 
nanoparticles with antibiotics, for instance vancomycin, erythromycin, penicillin G and 
amoxicillin, lead to improved and synergistic antimicrobial effects against both Gram-positive and 
Gram-negative bacteria, such as Escherichia coli (E.coli) and Staphylococcus aureus (S. aureus) 
(Fayaz et al., 2010; Rai et al., 2009; Shahverdi et al., 2007). While assorted uses of silver 
nanoparticles exist, lengthy contact to soluble silver comprising compounds could yield an 
irreparable pigmentation in the skin (argyria) and the eyes (argyrosis), along with added toxic 
effects, such as organ damage (liver and kidneys), irritation in the eyes and skin and alterations in 
blood cell counts (Drake and Hazelwood, 2005; Huh and Kwon, 2011). In contrast, metallic silver 
seems to pose a reduced risk to health, and silver nanoparticles have been proposed to possibly be 
non-toxic in certain studies (Johnston et al., 2010; Oberdörster et al., 2005). However, some 
studies stated concentration-dependent side effects of silver nanoparticles on mitochondrial 
activity (Braydich-Stolle et al., 2005; Hussain et al., 2005). The introduction of silver 
nanoparticles as likely antimicrobial nanomaterials necessitates clear and full clarifications of their 
possible toxicity (Huh and Kwon, 2011).  
 
2.7.2 Mechanism of action of silver nanoparticles 
Although the exact mechanism of action of silver on microbes is relatively unknown, the likely 
mechanism of action of metallic silver, silver ions and silver nanoparticles have been proposed in 
keeping with the structural and morphological modifications that originate in the bacterial cells 





(Rai et al., 2009). Silver nanoparticles specifically display effective antimicrobial properties 
compared to other salts due to their particularly large surface area, which affords better interaction 
with microorganisms. The nanoparticles attach themselves to the cell membrane and pierce into 
the bacteria. Silver nanoparticles interact with sulfur-containing proteins that are housed in the 
bacterial membrane, as well as with phosphorus containing compounds, such as DNA. Upon entry 
into the bacterial cell, silver nanoparticles form a low molecular weight area in the middle of the 
bacteria to which the bacteria agglomerate, thereby guarding the DNA from the silver ions. The 
nanoparticles favourably attack cell division, the respiratory chain inevitably causing cell death. 
The nanoparticles also discharge silver ions in the bacterial cells, which lead to improved 
bactericidal activity (Feng et al., 2000; Morones et al., 2005; Rai et al., 2009; Sondi and Salopek-
Sondi, 2004; Song et al., 2006). The various actions of silver nanoparticles against bacteria is 














Figure 9. The multiple bactericidal actions of silver nanoparticles. Adapted from Rai et al., 2012. 
 
2.7.3 Preparation of silver nanoparticles 
Various techniques for  synthesising silver nanoparticles have been described, and include 
chemical reduction (Lee and Meisel, 1982; Song et al., 2009; Wang et al., 2005a), thermal 
decomposition (Navaladian et al., 2007; Yang et al., 2007), laser ablation (Chen and Yeh, 2002; 





Mafuné et al., 2000a; Simakin et al., 2004), as well as sonochemical synthesis (Salkar et al., 1999). 
Of these, chemical reduction and laser ablation are the most frequently used synthetic routes. 
Chemical reduction comprises the reduction of metal salt, such as silver nitrate, in a suitable 
medium by means of numerous reducing agents e.g. citrate, borohydride, to yield colloidal 
suspensions integrated by nanoparticles (Evanoff and Chumanov, 2005). Lee and Meisel explained 
the citrate reduction technique in which, silver nitrate was dissolved in distilled water and brought 
to a boil. A solution of 1% sodium citrate was then added and continued to boil for 1 h. The 
subsequent colloid was greenish yellow in colour and its absorption maximum was at 420 nm (Lee 
and Meisel, 1982). An alternate technique, usually referred to as the Creightons method, utilises 
sodium borohydride as the reducing agent in place of citrate (Creighton et al., 1979). Generally, 
NaBH4 is diluted with water in a volumetric flask, with nitrogen being bubbled through it and then 
placed in an ice bath to avoid degradation. Thereafter, a solution of silver nitrate is diluted with 
water in a volumetric flask, and lastly, the cold solution of NaBH4 was added to the silver nitrate 
solution with vigorous stirring. This caused a colour change to light yellow, with stirring ensuing 
until the reaction reached room temperature. These synthetic procedures regularly produces 
particles of narrow size distribution (Ravindran et al., 2013). 
 
Thermal decomposition of metal complexes is another possible way of producing metal 
nanoparticles (Lee and Kang, 2004). If the product is metal and its decomposition temperature is 
low, thermal decomposition can be used for the synthesis of silver nanoparticles (Navaladian et 
al., 2007). Silver nanoparticles can also be synthesised via irradiation. Metal atoms having a few 
metal clusters, which are ablated from a metal rod via laser ablation and are aggregated into metal 
clusters with adequately larger sizes (Mafuné et al., 2000a). Laser irradiation can also formulate 
silver nanoparticles with a well-defined size and shape distribution (Simakin et al., 2004), with no 
additional chemical reducing agent being necessary (Ravindran et al., 2013). Additionally, the 
sonochemical reduction method produces high pressures and temperatures to reduce silver nitrate 
to metallic silver. This procedure is advantageous as it is relatively simple, efficient, and yields 
nanoparticles that are very small in size (Salkar et al., 1999). 
Finally, a pursuit for environmentally sustainable synthetic procedures has led to a few ‘green’ 
approaches (Raveendran et al., 2003). Such a method needs to be evaluated based on a green 
chemistry viewpoint that comprises: choosing an appropriate solvent medium, choosing an 





environmentally safe capping and reducing agent that contains extracts from bio organisms or 
plants, or a blend of biomolecules found in these extracts, for instance polysaccharides, amino 
acids, enzymes/proteins, and vitamins, and choosing nontoxic materials to stabilise the particles 
(Kalimuthu et al., 2008; Ravindran et al., 2013). 
 
2.7.4 Characterisation of silver nanoparticles 
There are a few methods for nanoparticle size characterisation, such as dynamic light scattering 
(DLS) (Cumberland and Lead, 2009; Martínez-Castañón et al., 2008), UV-Vis spectroscopy 
(Navaladian et al., 2007; Song et al., 2009; Wang et al., 2005a) using the move of the band gap of 
absorption in the UV-visible spectrum (Tomaszewska et al., 2013), transmission electron 
microscopy (TEM) (Chen and Yeh, 2002; Navaladian et al., 2007; Wang et al., 2005a), and atomic 
force microscopy (AFM). It is also possible to calculate particle sizes using X-ray diffraction 
(XRD) patterns (Navaladian et al., 2007; Wang et al., 2005a). DLS measures fluctuations in the 
intensity of scattered light, this being initiated by particle movement, and covers a size range from 
a few nanometres to approximately 3 microns. However, it is important to note that both 
approaches do not ‘measure’ particle sizes, they detect light scattering effects that are used to 
calculate particle sizes (Mehnert and Mäder, 2001; Müller et al., 2000).   
 
Conversely, UV-Vis spectroscopy measures the intensity of light that passes through a sample. 
Nanoparticles have unique optical properties that are sensitive to shape, size, concentration 
changes and agglomeration. The properties of metal nanoparticles are a result of the collective 
oscillations of conduction electrons that are excited by electromagnetic radiation, and are known 
as surface plasmon polariton resonances (SPPR) (Evanoff and Chumanov, 2005). These changes 
affect the refractive index next to the nanoparticles surface, thereby making it possible to 
characterise nanomaterials by UV-Vis spectroscopy (Tomaszewska et al., 2013).  
 
DLS and UV-Vis spectroscopy are easy to operate and fast methods for particle characterisation, 
particularly for colloidal samples (Huang et al., 2007; Leung et al., 2006). DLS and UV-Vis 
methods have numerous advantages, including simplicity, sensitivity and selectivity to 
nanoparticles, short measurement time, and no need for calibration. While DLS is extensively used 
for particle characterisation, there are certain difficulties, specifically when measuring samples 





that have large-size distribution or multimodal distributions (Khlebtsov and Khlebtsov, 2011; 
Zanetti-Ramos et al., 2009). The mean diameter of monodisperse colloids can be determined by 
DLS, however, with polydisperse colloids, there is a possibility that tiny objects can be concealed 
by bigger ones, which may result in them not being seen. 
 
When compared to DLS, TEM offers direct information about not only the morphology but also 
the size of particles at the same time. However, sample preparation for analysis is critical, which 
can be time consuming, necessitates high precision and the use of suitable reagents (Grobelny et 
al., 2011; He et al., 2000; Pethkar et al., 2001). Microscopic methods can also be challenging in 
terms of polydisperse samples, as there is a possibility of sample fractionation or particle 
aggregation during drying. 
 
AFM is gaining more appeal of late, and can be used to determine the geometric sizes of 
nanoparticles deposited on the surface (Tomaszewska et al., 2013). It uses the force acting amongst 
a surface and a probing tip, resulting in a spatial resolution of up to 0.01 nm for imaging. A distinct 
advantage of this method is ease of sample preparation (Mehnert and Mäder, 2001; Müller et al., 
2000).   
 
XRD is used to not only confirm the identity of nanoparticles by matching their diffractogram 
peaks to that of elemental silver, but it can also be used to confirm the size of nanoparticles using 
the Rietveld analysis (Martínez-Castañón et al., 2008).  
 
It is important to note that differences in the size of nanoparticles was observed with the different 
methods used, this being a function of the specificity of each rather than to any measurement 
errors. TEM and AFM measure geometric sizes of the nanoparticles deposited on the surface, thus 
results in these methods providing similar results. DLS measures hydrodynamic size, and light 
scatter from bigger silver nanoparticles is so intense that the scattered light from the smaller 
nanoparticles is screened. Consequently, the size of the measured nanoparticles can vary from 
those determined by AFM/TEM. Generally, each technique indicates that only monodisperse 
particles are present in the colloids (Tomaszewska et al., 2013). 
 





2.7.5 Stabilising agents in silver nanoparticle production 
Despite the fact that silver nanoparticles have displayed good performance as antibacterials, a 
significant challenge currently associated with their application is identifying strategies to provide 
the satisfactory stability of their dispersions to prevent their nanoparticles from aggregating.  
Generating spacious aggregates shows a noteworthy drop in the activity of the nanoparticles, 
which results in inferior performance and a loss of antibacterial activity (Kvitek et al., 2008; Shi 
et al., 2015). Therefore, silver nanoparticles are frequently fabricated by reducing silver nitrate, 
which are then stabilised by capping agents to reduce the risk of aggregation that arises from the 
high surface area of nanoparticles (Shi et al., 2015). To prevent particle agglomeration, numerous 
surfactants and polymers have been investigated to stabilise these metal colloids (Li et al., 2015).  
 
The improved stability of aqueous dispersions of the silver nanoparticles can be attained through 
two types of protecting mechanisms. The first mechanism of the dispersion system stabilisation is 
centred on an electrostatic repulsion. The addition of an ionic surfactant can enhance the surface 
charge of the disperse phase and provide electrostatic protection of the nanoparticles, which can 
result in their adhering to one another. Cetyltrimethylammonium chloride or bromide (CTAC, 
CTAB) (Yu and Yam, 2005), as the cationic surfactant group, and sodium dodecyl sulfate (SDS) 
(Mafuné et al., 2000b), as the anionic surfactant group, have been utilised in numerous studies and 
are considered stabilising agents of considerable importance (Yu and Yam, 2005; Zheng et al., 
2003). The mechanism of surfactant adsorption, with regard to silver nanoparticle associations 
with ionic surfactants, has not yet been adequately explained. Nevertheless, a likely mechanism 
for arranging of the SDS molecules on the nanoparticle surface can be the hydrophilic groups of 
the surfactant molecules are adsorbed on the silver nanoparticle surface and the hydrophobic tails, 
are arranged outward to provide the first layer. Therefore, a counter-layer is arranged in the 
opposite way, causing interpenetration of the surfactant hydrophobic tails among the two layers, 
with the hydrophilic groups directed outward (Chen and Yeh, 2002; Kvitek et al., 2008). 
 
The second one, which is based on the steric repulsion, shows a stabilising effect with the aid of 
polymers and non-ionic surfactants that are instantly adsorbed at the phase interphase (Hunter, 
2001). The equilibrium between the attractive and the repulsive forces is mainly reliant on the 
thickness of the adsorbed layer (Chou and Lai, 2004; Luo et al., 2005), and, in the case of polymers, 





is reliant on the chain length as well as on its adsorption mode. When compared to polymers, the 
non-ionic surfactants are adsorbed in a more compressed manner at the surface of the nanoparticles  
that gives an exceptional stabilising effect (Kvitek et al., 2008; Liz-Marzán and Lado-Tourino, 
1996). Polymers studied so far for stabilising silver nanoparticles include polyethylene glycols 
(PEG) (Popa et al., 2007), poly(vinylalcohols) (PVA) (Chou and Ren, 2000), 
poly(vinylpyrrolidones) (PVP) (Silvert et al., 1996), polyacrylamides (Chen et al., 2006), 
polyurethanes (PU), (Chou et al., 2006), as well as highly branched molecules such as dendrimers 
(Esumi et al., 2000), hyperbranched polymers (Zhang et al., 2008) and star polymers (Huang et 
al., 2012). 
 
2.8 Silver as a model antimicrobial agent 
Silver is a potent antimicrobial agent, particularly in its’ positively charged ionic form [e.g. silver 
nitrate (Figure 10a) and silver acetate (Figure 10b)], as it displays a strong toxicity to a wide range 
of micro-organisms, and concurrently has a particularly low human toxicity (Dallas et al., 2011; 
Gibbins and Warner, 2005; Liau et al., 1997).  
 
                                
        (a)                                             (b)  
Figure 10. Types of ionic silver: (a) Silver nitrate, (b) silver acetate 
 
Antimicrobial silver is widely used to combat organisms associated with burns and wounds 
(Gibbins and Warner, 2005). In addition, silver-based medical preparations are available and 
frequently used in biomedical material coatings, such as silver impregnated catheters and dressings 
for wound healing (Dallas et al., 2011). Silver is also capable of disturbing key functions in a 
microorganism that causes AMR. It has a high affinity for negatively charged side groups on 
biological molecules, such as carboxyl, phosphate, sulfhydryl and others dispersed throughout 
microbial cells. It thereby transforms the macromolecule’s molecular structure via this binding 
reaction, rendering it useless to the cell (Gibbins and Warner, 2005). Concomitantly, silver can 
attack numerous sites within the cell, incapacitating critical physiological functions, such as cell 





wall synthesis, protein folding and function, membrane transport, nucleic acid (such as RNA and 
DNA) synthesis, as well as translation and electron transport, which are vital for cell energy 
production. Dispossessed of such key functions, bacterial growth can either be inhibited or, more 
frequently, the microorganism is killed (Gibbins and Warner, 2005). It is highly improbable that 
resistance to antimicrobial silver could ever develop, as this would mean that an organism would 
have to undertake concurrent mutations in every critical function within just a single generation to 
evade the compounds multiple actions. (Gibbins and Warner, 2005) This is a crucial factor to 
consider when developing new antimicrobial materials to overcome resistance. However, it should 
be noted that silver is nontoxic to human cells only in minute concentrations (Pal et al., 2007). 
This clearly limits the use of metallic silver and silver ion as an antibacterial agent only up to 
concentrations that are non-toxic to eukaryotic cells.  
 
2.9 Conclusions 
This chapter highlighted the current status of infectious diseases, its drug therapy and their 
associated limitations. Strategies aimed at overcoming the current limitations associated with 
antibiotic drugs include complexes of silver and dendrimers, as well as star polymer stabilised 
silver nanoparticles. This literature review showed that although studies on silver nanoparticles 
and silver nanocomposites have been widely reported, very little work has been done on dendrimer 
silver salts and their potential uses as antimicrobial agents.  Another noteworthy point was that a 
significant application difficulty related to silver nanoparticles is the satisfactory stability of their 
dispersions. The search for new polymers as stabilising agents is therefore of great importance to 
facilitate the application of silver nanoparticles as antimicrobials. 
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CHAPTER 3. PUBLISHED PAPER 
3.1 Introduction  
The following paper was published in an international peer reviewed ISI journal and reports the 
original research from data generated during this study: 
Suleman, N., Kalhapure, R., Mocktar, C., Rambharose, S., Singh, M., Govender, T., 2015. Silver 
salts of carboxylic acid terminated generation 1 poly (propyl ether imine) (PETIM) dendron and 
dendrimers as antimicrobial agents against S.aureus and MRSA. Royal Society of Chemistry 
Advances, 5, 34967-34978. (IF = 3.708) 
Ms. N Suleman contributed to the design of the project, and the preparation and characterisation 
of all G1 PETIM dendron/dendrimers and PETIM-silver salts in terms of synthesis, IR, NMR, 
HRMS, in vitro cytotoxicity and in vitro antimicrobial studies, along with interpretation of the data 
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interpretation of characterisation data of all synthesised materials in terms of IR, NMR and HRMS. 
Dr C. Mocktar assisted with the in vitro antimicrobial study. Mr S. Rambharose and Dr M. Singh 
assisted with the in vitro cytotoxicity study. The remaining author served as supervisor. 
This chapter is presented in the required format of the journal and is the final revised and accepted 













3.2 Published paper  
Silver salts of carboxylic acid terminated generation 1 poly (propyl ether 
imine) (PETIM) dendron and dendrimers as antimicrobial agents against 
S.aureus and MRSA 
Nadia Sulemana, Rahul Kalhapurea, Chunderika Mocktara, Sanjeev Rambharosea, 
Moganavelli Singhb and Thirumala Govendera 
 
Abstract 
Novel therapeutic strategies are essential to address the current global antimicrobial resistance 
crisis. Branched molecules with multiple peripheral functionalities, known as dendrimers, have 
gained interest as antimicrobials and have varying levels of toxicity. Silver displays activity against 
several micro-organisms only in its positively charged form. In this study, silver salts of generation 
1(G1) poly (propyl ether imine) (PETIM) dendron and dendrimers were synthesised and evaluated 
for their antimicrobial potential against sensitive and resistant bacteria. The purpose was to exploit 
the multiple peripheral functionalities of G1 PETIM dendron and dendrimers for the formation of 
silver salts containing multiple silver ions in a single molecule for enhanced antimicrobial activity 




at the lowest possible concentration. G1 PETIM dendron, dendrimers and their silver salts were 
synthesised and characterised by FT-IR, 1H NMR and 13C NMR. PETIM silver salts were 
evaluated against Hep G2, SKBR-3 and HT-29 cell lines for their cytotoxicity using the MTT 
assay. The G1 PETIM dendron/dendrimers, silver nitrate and silver salts of the G1 dendron 
(compound 13), G1 dendrimer with an aromatic core (compound 14) and an oxygen core 
(compound 15) were evaluated for activity against S. aureus and methicillin-resistant S. aureus 
(MRSA) by the broth dilution method. PETIM silver salts were found to be non-cytotoxic even up 
to 100 µg/ml. Minimum inhibitory concentration values of compounds 13, 14 and 15 against S. 
aureus were 52.1, 41.7, and 20.8 μg/ml while against MRSA they were 125.0, 26.0 and 62.5 μg/ml 
respectively. The calculated fractional inhibitory concentration index further indicated that 
compound 14 specifically displayed additive effects against S. aureus and synergism against 
MRSA. The enhanced antimicrobial activities of the PETIM dendron/dendrimer-silver salts 
against both sensitive and resistant bacterial strains widen the pool of available pharmaceutical 
materials for optimizing treatment of bacterial infections. 
 




Infectious diseases, a significant portion of which are of bacterial origin, are one of the leading 
causes of death globally for adults and children and remains a major public health issue for 
developed and developing countries. 1 While antibiotics revolutionized the treatment of infections, 
thereby saving millions of lives, eighty years after their discovery, their effectiveness is seriously 
threatened by antimicrobial resistance (AMR). 2 This nullifies the use of even the most potent 
antibiotics, which leads to patient suffering and/or dying due to infection control failure, and 
results in escalated health care costs. 3  
 
Globally, resistant bacterial strains, such as methicillin-resistant Staphylococcus aureus 
(MRSA) 4, vancomycin-resistant Enterococcus (VRE) 5 and vancomycin-resistant Staphylococcus 




aureus (VRSA), 6 have become significant threats in community settings and hospitals for 
treatment of infections. Furthermore, if current escalating trends in AMR continue, several 
important procedures, such as cancer chemotherapy, organ transplantation and hip and other joint 
replacements, could no longer be performed for  fear that the related compromised immune system 
might put the patients at severe risk of acquiring a difficult to treat and ultimately fatal infection. 
7 The global AMR crisis is amplified by the decreasing development of new antibiotics by 
pharmaceutical companies8, with 20 novel classes of antibiotics being developed in between 1930-
1962 9, 10, and only two of them have been marketed.11-14 This decline in drug development is due 
to the high costs and lengthy delays associated with developing a new chemical entity, high 
attrition rates at final testing, and increasing AMR, which makes finding a new drug very 
expensive and limits the return on investment. 3, 15 
It is therefore essential that alternative novel antimicrobial therapeutic strategies are 
explored to address the imminent crisis with conventional antibiotics. Alternative options currently 
being investigated are novel drug delivery systems for existing antibiotics, such as silver 
nanoparticles 16-18, solid lipid nanoparticles 19-21, liposomes 22-24 and the synthesis of new 
antimicrobial materials, such as  dendrimers 25-27 and antimicrobial peptides. 28 
Silver is a potent antimicrobial agent, particularly in its positively charged ionic form, as it 
displays a strong toxicity to a wide range of micro-organisms and concurrently has a particularly 
low human toxicity. 29-31 Antimicrobial silver is widely used to combat organisms associated with 
burns and wounds. 30 In addition, silver-based medical preparations are available and frequently 
used in coatings of biomedical materials, such as silver impregnated catheters and dressings for 
wound healing. 29 Silver is also capable of disturbing key functions in a microorganism that causes 
AMR. It has a high affinity for negatively charged side groups on biological molecules, such as 
carboxyl, phosphate, sulfhydryl and others dispersed throughout microbial cells. It thereby 
transforms the macromolecule’s molecular structure via this binding reaction, rendering it useless 
to the cell. 30 Concomitantly, silver can attack numerous sites within the cell, incapacitating critical 
physiological functions, such as cell wall synthesis, protein folding and function, membrane 
transport, nucleic acid (such as RNA and DNA) synthesis, and translation and electron transport, 
which are vital for cell energy production. Dispossessed of such key functions, bacterial growth 
can either be inhibited or, more frequently, the microorganism is killed. 30 It is highly improbable 
that resistance to antimicrobial silver could ever develop, as this would mean that an organism 




would have to undertake concurrent mutations in every critical function within just a single 
generation to evade the compounds multiple actions. 30 This is a crucial factor to consider when 
developing new antimicrobial materials to overcome resistance. However, it should be noted that 
silver is nontoxic to human cells only in minute concentrations. 32 This clearly limits the use of 
metallic silver and silver ion as an antibacterial agent only up to concentrations that are non-toxic 
to eukaryotic cells.  
Dendrimers are repeatedly branched molecules or nano-sized, radially symmetric 
molecules that have a well-defined, uniform and monodisperse structure that consists of branches 
surrounding a core. 33, 34 The availability of several functional surface groups and their low 
polydispersity make them a rich source for finding novel and unique properties. 33, 35 Due to these 
very distinctive properties, and the fact that they can be adapted to therapeutic needs, they are 
regarded as model carriers for small molecule drugs and biomolecules. 26 Dendrimers have gained 
further interest as likely antimicrobial agents due to the availability of numerous end groups and 
their compressed structure. 36, 37 Therefore, if any one of the functional groups is capable of 
interacting with a target, other groups within close proximity of one another could make synergistic 
interactions for antimicrobial activity possible. 36 Specific interactions (e.g. quaternary ammonium 
based dendrimers) aim to eliminate bacterial/viral infections by inhibiting the growth of microbes, 
thereby killing them and nonspecific interactions (e.g. oligosaccharide based dendrimers), and 
preventing the initial attachment between bacteria/viruses and host cells. 36  
 
It has also been highlighted that dendrimers show promising biocompatibility in general 26, 
which is essential for their application, and can themselves be used as antimicrobial agents. 38-41 
Consequently, highly potent dendrimer based antibacterial agents have been synthesised. 38, 40 
Currently, the most extensively used dendrimers in drug delivery include poly propylene imine 
(PPI), polylysine, triazine 42 and polyamidoamine (PAMAM), the latter being the first and most 
commonly studied. 26 Unfortunately, its uses are constrained by  limitations such as cytotoxicity 
resulting from its amine-terminated nature 43 and as a result, there are no commercially available 
dendrimer based formulations for systemic administration. 42 Researchers have recognized the 
potential of developing complexes of silver and dendrimers to enhance antimicrobial activity, with 
Balogh et al. having prepared PAMAM dendrimer based silver complexes  44, which showed 




enhanced antimicrobial effect, creating a new and potent antimicrobial agent for biomedical 
applications. 
A fairly new class of dendrimers, known as the poly (propyl ether imine) (PETIM) 
dendrimers, has been reported to have good biocompatibility when compared to commercial 
PAMAM dendrimers, and has been effectively applied for encapsulation of ketoprofen for 
sustained drug delivery. 42 Although it has several advantages, such as non-cytotoxicity and easy 
functional group modification at the periphery, its potential for antimicrobial therapy has not been 
exploited. This study is therefore the first combination of PETIM dendrimers and silver to identify 
novel antimicrobial materials effective against both sensitive and resistant bacterial strains, and 
will widen the pool of available pharmaceutical materials to optimize the treatment of bacterial 
infections.  
In this study, a generation 1 (G1) PETIM dendron and two PETIM dendrimers containing 
a carboxylic acid function at the periphery were synthesised and reacted with silver nitrate to form 
dendrimer-silver salts. The PETIM dendrimers were used as templates to contain the silver ions. 
The rationale for using PETIM dendrimer and dendron as a template to contain silver ions were: 
i) more than one silver ion can be accommodated on a single PETIM dendrimer or dendron, as it 
contains multiple carboxylic acid functions at the periphery; ii) PETIM silver complexes is 
nontoxic to mammalian cells due to the biocompatibility of PETIM dendrimers; and iii) PETIM 
on its own could display antimicrobial activity, thus the potential antimicrobial activity of PETIM 
silver complexes may display additive or synergistic effects. Published studies on silver complexes 
of organic compounds as antimicrobial agents mostly include two organic molecules complexed 
with one silver ion through a chemical bond formation. 45, 46 In the present investigation, our goal 
was therefore to exploit the multiple peripheral functionalities of biocompatible PETIM dendron 
and dendrimers to form silver salts containing multiple silver ions in a single molecule for 
enhanced antibacterial activity at the lowest possible concentration. The intention was to study the 
effect of the number of silver ions per molecule of these dendrimer silver salts on antimicrobial 
efficacy against both sensitive and resistant strains. For this reason, a G1 PETIM dendron (two 
carboxylic acid functions at the periphery), G1 PETIM dendrimer with oxygen core (four 
carboxylic acid functions at the periphery) and G1 PETIM dendrimer with aromatic core (six 
carboxylic acid functions at the periphery) were selected. The results of the investigations are 
reported in this paper.  




Results and Discussion 
Synthesis 
In this study three different compounds were employed, viz., a G1 PETIM dendron 4, a PETIM 
dendrimer with an aromatic core 7, and another PETIM dendrimer with an oxygen core 12. 
Synthetic steps for these compounds are depicted in Scheme 1-3 and explained hereunder.  
The dendron was prepared using 3-amino-1 propanol 1 and excess tert-butyl acrylate 2 to 
afford an ester in good yield. Thereafter the resulting ester was deprotected (AcCl, H2O) to obtain 
the free carboxylic acid containing G1 PETIM dendron 4 (Scheme 1). 
Scheme 1 Synthesis of G1 PETIM dendron. 
 
The two dendrimers synthesised were prepared with slight modifications in a previously 
reported method 47. Upon synthesis of the dendron 3, its attachment to a selected core was carried 
out. Compound 3 was coupled with 1,3,5-benzenetricarbonyl trichloride 5 in the presence of 
DMAP to attain 6. Thereafter the resulting ester was deprotected via an acetyl chloride and water 
system to attain the free carboxylic acid containing G1 PETIM dendrimer with an aromatic core 7 
(Scheme 2).  
 





Scheme 2 Synthesis of G1 PETIM dendrimer containing an aromatic core. 
 
Bis-nitrile 9 was attained from acrylonitrile 8 and aqueous NaOH (40%). Bis-nitrile was 
subjected to successive reactions; i.e. reduction of the nitrile using LiAlH4 to a diamine 10; 
Michael addition of tert-butyl acrylate to afford the tetrakis 11; and deprotection of the ester (AcCl, 
H2O) to attain the free carboxylic acid containing G1 PETIM dendrimer with an oxygen core 12 
(Scheme 3).  
 





Scheme 3 Synthesis of G1 PETIM dendrimer containing an oxygen core. 
 
Preparation of PETIM-silver salts (Scheme 4) 
PETIM silver salts (13, 14 and 15) were all prepared in a similar method where silver was reacted 
with 4, 7 and 12 to afford these PETIM-silver salts. 





Scheme 4.  Synthesis of silver salts of G1 PETIM dendron and dendrimers. 
Characterisation  
The synthesised dendron and dendrimers were characterised by FT-IR, 1H NMR, 13C NMR and 
HRMS and were compared with the literature values. 47 Synthesis of the silver salts were 
accomplished via reaction of silver nitrate with the corresponding dendron/dendrimer acid. 
Formation of silver salts was supported by observing the shifts in the positions of characteristic IR 
frequencies of carboxylic groups in the dendron and dendrimers. 
The main feature which allows one to differentiate a carboxylic acid from all other carbonyl 
compounds is a broad absorption band due to the strongly hydrogen bonded O-H stretching 
vibrations which extends from 3300 cm-2500 cm -1. The transformation of the ester function to a 
carboxylic acid was confirmed by the presence of this characteristic peak in FT-IR spectrum. In 
addition, all carboxylic acid terminated dendron/dendrimers exhibited a peak in the range of 1707-
1714 cm-1 indicating the presence of a C=O stretching band of the –COOH group. The aliphatic 
C-H stretching band appeared as a jagged peak near 3000 cm-1. Coupled vibrations involving C-O 
stretching were observed in the range of 1459-1399 cm-1. Salts of carboxylic acids do not display 




any of the carbonyl bands rather bands owing to the asymmetric and symmetric stretching 
vibrations of the equivalent carbon-oxygen bonds. They are observed at 1610-1550 cm-1 and 1420-
1300 cm-1 respectively which provides evidence for the carboxylate anion 48. In our study the peaks 
in the range of 1459-1332 cm-1 from carboxylic acid terminated dendron and dendrimers 
disappeared and appearance of symmetric stretching vibrations in the range of 1288-1233 cm-1 
was observed (Fig. 1, 2 and 3) after transforming them into their respective silver salts. Thus, the 
presence of the bands because of symmetric stretching vibrations of the equivalent carbon-oxygen 
bonds strongly confirms the formation of silver salts of G1 PETIM dendron and dendrimers. 
Further attempts to characterise silver salts using elemental analysis were not successful because 
of their hygroscopic nature. 47                             









Fig. 1 (a) FT-IR spectra comparing G1 PETIM dendron 4 and G1 PETIM dendron-silver salt 13; 
(b) G1 PETIM dendrimer (aromatic core) 7 and G1 PETIM dendrimer (aromatic core) -silver salt 
14 and (c) G1 PETIM dendrimer (oxygen core) 12 and G1 PETIM dendrimer (oxygen core) - 
silver salt 15 
 
In vitro cytotoxicity study 
An in vitro cell culture system was used to determine the biological efficacy of the PETIM silver 
salts. The MTT assay, which is based on the biochemical reduction of MTT by viable cells, was 
used to determine the cytotoxicities of the PETIM silver salts against Hep G2, HT-29 and SK-BR-
3 cell lines. 49 Determining cell viability using cytotoxicity assays are basic steps in toxicology 
that explain the cellular response to a compound by providing information on cell death and their 
metabolic activities. 50 Cell viability of between 80% and 95% were observed for all the PETIM 
silver salts across all the cell lines (Fig. 2). The comparative results between the individual PETIM 
dendron/dendrimers, their respective concentrations of silver nitrate, and their subsequent 
combinations (PETIM silver salts) were tested for cytotoxicity and are represented in Fig. 3. 
 
























Fig. 2a Cytotoxicity assay against Hep G2 cells, displaying percentage cell viability after exposure 




to various concentrations of PETIM silver salts [G1 PETIM dendron-silver salt 13; G1 PETIM 
dendrimer (aromatic core)-silver salt 14; G1 PETIM dendrimer (oxygen core)-silver salt 15] to 
































Fig. 2b Cytotoxicity assay against HT-29 cells, displaying percentage cell viability after exposure 
to various concentrations of PETIM silver salts [G1 PETIM dendron-silver salt 13; G1 PETIM 
dendrimer (aromatic core)-silver salt 14; G1 PETIM dendrimer (oxygen core)-silver salt 15] to 
Hep G2 cells. Results are presented as mean ± SD. (n = 6). 































Fig. 2c Cytotoxicity assay against SK-BR-3 cells, displaying percentage cell viability after 
exposure to various concentrations of PETIM silver salts [G1 PETIM dendron-silver salt 13; G1 
PETIM dendrimer (aromatic core)-silver salt 14; G1 PETIM dendrimer (oxygen core)-silver salt 
15] to Hep G2 cells. Results are presented as mean ± SD. (n = 6). 
 





Fig. 3a Cytotoxicity assay on Hep G2 cell lines, comparing percentage cell viability after exposure 
to PETIM silver salts against their individual parent dendron/dendrimer as well as silver nitrate 
concentrations. Results are presented as mean ± S.D. (n = 6). *denotes significant difference 
compared to the respective silver nitrate (P < 0.05) [G1 PETIM dendron 4; G1 PETIM dendrimer 
with aromatic core 7; G1 PETIM dendrimer with oxygen core 12 ; G1 PETIM dendron-silver salt 
13; G1 PETIM dendrimer (aromatic core)-silver salt 14; G1 PETIM dendrimer (oxygen core)-
silver salt 15]. 





Fig. 3b Cytotoxicity assay on HT-29 cell lines, comparing percentage cell viability after exposure 
to PETIM silver salts against their individual parent dendron/dendrimer as well as silver nitrate 
concentrations. Results are presented as mean ± S.D. (n = 6). *denotes significant difference 
compared to the respective silver nitrate (P < 0.05) [G1 PETIM dendron 4; G1 PETIM dendrimer 
with aromatic core 7; G1 PETIM dendrimer with oxygen core 12 ; G1 PETIM dendron-silver salt 
13; G1 PETIM dendrimer (aromatic core)-silver salt 14; G1 PETIM dendrimer (oxygen core)-
silver salt 15]. 





Fig. 3c Cytotoxicity assay on SK-BR-3 cell lines, comparing percentage cell viability after 
exposure to PETIM silver salts against their individual parent dendron/dendrimer as well as silver 
nitrate concentrations. Results are presented as mean ± S.D. (n = 6). *denotes significant difference 
compared to the respective silver nitrate (P < 0.05) [G1 PETIM dendron 4; G1 PETIM dendrimer 
with aromatic core 7; G1 PETIM dendrimer with oxygen core 12 ; G1 PETIM dendron-silver salt 
13; G1 PETIM dendrimer (aromatic core)-silver salt 14; G1 PETIM dendrimer (oxygen core)-
silver salt 15]. 
 
The range of cell viability obtained in this study indicates that the PETIM silver salts 
displayed a low toxicity level on all cell lines studied. 51 The results also showed that the effects 
of the compounds on the cell line were not dose dependent, as no dose dependent trends were 
observed for any of the PETIM silver salts at the various treatment concentrations against any of 
the cell lines (Fig. 2).  These PETIM silver salts displayed a greater percentage cell viability when 
compared to their respective concentrations of silver nitrate (Fig. 3). Reduced cytotoxicity of the 
PETIM silver salts may be due to their close-to-neutral net surface charge, which had little effect 
on membrane integrity. 52  These results are in line with previous findings, where acetamide-
terminated G5 PAMAM dendrimers revealed to have little effect on membrane integrity, whereas 




positively charged G5 PAMAM dendrimers reduced the integrity of the cell membrane and 
prompted the release of cytoplasmic membrane proteins, lactate dehydrogenase and luciferase. 52, 
53 The PETIM silver salts therefore have a statistically greater cell viability than the silver nitrate 
(P < 0.05) (Fig. 5) and slightly higher cell viability when compared to the PETIM 
dendron/dendrimers. Therefore, they can be considered non-toxic with potential for use in the 
biomedical and pharmaceutical fields. 
In vitro antimicrobial evaluation 
The antimicrobial activities of silver nitrate, the PETIM dendron/dendrimers and the PETIM silver 
salts were investigated against S. aureus and MRSA. A summary of the results for the MIC values 
for in vitro antimicrobial activity is presented in Table 1. MIC values for the different 
concentrations of silver nitrate against S. aureus were 112.5, 87.5 and 77.5 μg/ml respectively, and 
against MRSA they were 93.7, 210 and 77.5 μg/ml respectively (Table 1). Ionized silver brings 
about structural changes in bacterial cell walls and nuclear membranes as it is highly reactive when 
it binds to tissue proteins. Thus it results in cell distortion and even cell death. Silver can also bind 
to bacterial DNA and RNA, and can therefore inhibit bacterial replication. These antimicrobial 
properties of silver are dependent on the quantity and the rate at which silver is released. 54, 55 The 
MIC values for the PETIM dendron/dendrimers, i.e. 4, 7 and 12 against S. aureus and MRSA, 
were all 500 μg/ml (Table 1). The MIC values obtained for the PETIM dendron/dendrimers 
indicate that the PETIM dendron/dendrimers alone do have some antimicrobial activity, although 
low, against the selected bacteria. Higher antimicrobial activity has been reported for both 
unmodified dendrimers and dendrimers, with additional surface modifications such as PAMAM 
dendrimer ammonium salts 38, and PPI dendrimers modified with maltotriose 25% and 100%. 39 
However, the unmodified dendrimers displayed higher levels of cytotoxicity when compared to 
the surface modified dendrimers due to the cationic nature of these dendrimers. 56 As the PETIM 
dendrimers in our study displayed good cell viability due to their anionic nature, this nullifies the 
need for surface modification procedures to minimize the toxicity. Although these MIC values are 
higher when compared to surface modified and unmodified dendrimers, such as PAMAM and PPI 
against gram positive bacteria, this does confirm for the first time the antimicrobial activity of G1 
PETIM dendron and dendrimers (4, 7 and 12). 
 




The MIC values for the PETIM silver salts, i.e. 13, 14 and 15 investigated in this study, 
were 52.1, 41.7, and 20.8 μg/ml against S. aureus respectively, while against MRSA they were 
125.0, 26 and 62.5 μg/ml respectively (Table 1). An increase in antimicrobial activity was 
observed for all salts when compared to silver nitrate and PETIM dendron/dendrimers alone. This 
may be a result of a high local concentration of silver ions available at the periphery of the PETIM 
silver salts. Antimicrobial activity was reported to be less when internal complexes were applied, 
showing that accessibility of the silver is a vital factor, and that a high local concentration of silver 
needs to be accessible to have a significant effect on microorganisms. 44 The MIC values of the 
salts of PETIM dendron/dendrimers were markedly reduced for G1 PETIM-dendron silver salt 13 
and G1 PETIM dendrimer (oxygen core)-silver salt 15 against S. aureus, and G1 PETIM 
dendrimer (aromatic core)-silver salt 14 against both organisms. Compound 13 and 15 exhibited 
42% and 33% greater activity against S. aureus respectively when compared to MRSA. However, 
compound 14 displayed 62 % greater activity against MRSA than S. aureus. The PETIM silver 
salts showed different degrees of antibacterial activity in relation to the bacterial species used in 
this study. Compound 14 displayed greater antibacterial activity against MRSA than S. aureus.  
Certain dendrimers displayed potent and broad antimicrobial activity against S. aureus 37, as well 
as a selectivity toward this particular bacterial species. 39 Polcyn et al also recently synthesised a 
range of modified dendrimers and interestingly, they too identified one particular dendrimer as 
having strong activity against MRSA 37, similar to the antimicrobial activity of compound 14 used 
in this study. Wang et al, performed antimicrobial testing on norfloxacin-loaded solid lipid 
nanoparticles for a 144 h time period, and the results indicated antimicrobial activity for an 
extended time period. 19  Similarly, the antimicrobial activity of 13, 14 and 15 were tested over a 
72 h period, with the results being consistent throughout this time span, indicating that they have 
the potential for sustained antimicrobial activity. 
 
MIC values alone did not contribute toward a clear indication of the combined effects of 
the PETIM dendron/dendrimers and silver nitrate. Hence, the effects of the combination of G1 
PETIM dendron/dendrimers and silver nitrate were also investigated, and these effects were 
evaluated using ƩFIC. A summary of the results for the ƩFIC values for in vitro antimicrobial 
activity experiments is presented in Table 2. All of the combinations displayed different degrees 
of effectiveness against the bacteria tested, and no antagonistic relations were observed. 




Compound 13 presented a ƩFIC value of 1.58 against MRSA (Table 2), which represents 
indifference (Table 3). Compound 13 and 14 presented a ƩFIC value of 0.57 and 0.56 against S. 
aureus (Table 2), and 15 presented a ƩFIC value of 0.93 against MRSA (Table 2), which are all 
indicative of additive effects (Table 3). Compound 14 presented a ƩFIC value of 0.18 against 
MRSA (Table 2) and 15 presented a ƩFIC value of 0.31 against S. aureus (Table 2), which signify 
synergistic effects (Table 3). Of the three PETIM silver salts tested, 13 was observed to be the 
least active salt, whereas 14 was most active. This pattern of antibacterial activity of G1 PETIM-
silver salts against both S. aureus and MRSA can be correlated to the structures of the compounds. 
The order of antibacterial potency of dendron/dendrimer-silver salts was G1 PETIM dendrimer 
(aromatic core)-silver salt 14 (six Ag+ ions in the structure) > G1 PETIM dendrimer (oxygen core)-
silver salt 15 (four Ag+ ions in the structure) > G1 PETIM dendron-silver salt 13 (two Ag+ ions in 
the structure).  The G1 PETIM-silver salt with the highest number of carboxylic acid functions, 
and ultimately the highest number of Ag+ ions, had the greatest antibacterial activity. As the G1 
PETIM-silver salts contain positively charged Ag+ ions and the bacterial cell wall has an overall 
negative charge, which has more affinity towards positively charged compounds, it may be 
possible that 14 had the best activity because of the highest number of Ag+ ions present. The 
synergistic effect of 14 could therefore be a result of the combination of different mechanisms of 
actions of both silver and the dendron/dendrimers. Silver is known for its growth inhibitory 
capacity against microorganisms 57, and by using dendrimers as a template to incorporate silver, 
dendrimers themselves can become potent antimicrobials. 58 This activity can then be further 
enhanced if the functional groups of the dendrimers are within close proximity to one another. 36  
The interesting differences in activity of the three compounds against S. aureus and MRSA 
as well as specifically the significant synergistic activity against MRSA as compared to S. aureus 
in 14 may be due to differences in the structure and composition of their cell walls. For example 
one of the most widely reported mechanisms of resistance in S. aureus is the development of a 
modified penicillin binding protein (PBP)  known as PBP 2a found in MRSA. 59, 60 Biosynthesis 
of peptidoglycan, which comprises the outermost layer of Gram-positive bacteria, is achieved by 
the membrane-bound enzymes PBP.59 With MRSA the modified PBP known as PBP 2a, is 
intrinsically resistant to inhibition by β-lactams and stays active even in the presence of antibiotics 
that typically inhibit most endogenous PBP enzymes, thereby replacing their functions in cell wall 
synthesis and permitting growth in the presence of β-lactam inhibitors such as Methicillin. 59  




The significant increase in activity of 14 against MRSA may be attributed to its higher 
valency compared to 15. The higher valency of 14 might have resulted in better binding affinity to 
PBP 2a of MRSA than PBP of S. aureus. This plausible mechanism of action could be supported 
by the recent findings where multivalent vancomycin-conjugated G5 PAMAM dendrimers 
exhibited enhancement in avidity in the cell wall models of S. aureus and VRSA as compared to 
free vancomycin. In this particular study authors have observed that the vancomycin-conjugated 
PAMAM dendrimers had binding avidity of 2-3 and 5 orders of magnitude with (D)-Ala-(D)-Ala, a 
cell wall precursor of S. aureus and (D)-Ala-(D)-Lac, a cell wall precursor of VRSA respectively. 
61 
The absence of PBP 2a in S. aureus could have been the reason behind low activity of 14 against 
S. aureus as compared to 15. In the case of S. aureus 15 may have greater binding affinity to PBP 
resulting in its higher antibacterial activity against S. aureus than 14.  
Whilst the paper by Choi et al attempts to provide a mechanistic understanding of the 
vancomycin-conjugated G5 PAMAM dendrimers against S. aureus and VRSA, there are no such 
mechanistic studies available in the literature using novel materials and delivery systems against 
S. aureus and MRSA. There is also the possibility of multiple simultaneous mechanisms of actions 
of 14 and 15 against both S. aureus and MRSA, therefore, the mechanism of action postulated to 
explain the differences in antibacterial activity of 14 and 15 against MRSA and S. aureus 
respectively is a hypothesis based on previous literature and needs to be confirmed by future in 












Table 1. MIC results for in vitro antimicrobial activity of PETIM dendron/dendrimers, PETIM 






S. aureus MRSA 
G1 PETIM dendron 4 500* 500* 
Silver Nitrate  112.5* 93.7* 
G1 PETIM dendron-silver salt 13 52.1±18.04 125* 
   
G1 PETIM dendrimer with an aromatic core 7 500* 500* 
Silver Nitrate 87.5* 210* 
G1 PETIM dendrimer (aromatic core)-silver salt 14 41.7±18.04 26±9.04 
   
PETIM dendrimer with oxygen core 12 500* 500* 
Silver Nitrate 77.5* 77.5* 
G1 PETIM dendrimer (oxygen core)-silver salt 15 20.8±11.07 62.5* 
   *denotes SD = 0 
 
 
Table 2. ƩFIC results for in vitro antimicrobial activity of the PETIM silver salts. 
Sample ƩFIC  Results 
S. aureus MRSA  S. aureus MRSA 
G1 PETIM dendron-silver salt 
13 
0.57 1.58  Additive Indifference 
G1 PETIM dendrimer 
(aromatic core)-silver salt 14 
0.56 0.18  Additive Synergy 
G1 PETIM dendrimer (oxygen 
core)-silver salt 15 
0.31 0.93  Synergy Additive 
 
 





Materials and methods 
Acrylonitrile, tert-butyl acrylate and 3-amino-1-propanol were purchased from Alfa Aesar 
(Germany). 4 – (dimethylamino) pyridine (DMAP), lithium aluminum hydride (LiAlH4), acetyl 
chloride (AcCl), 1,3,5-benzenetricarbonyl trichloride, silver nitrate and silica gel were purchased 
from Sigma-Aldrich (USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) was obtained from Merck Chemicals (Germany). All other chemicals and solvents used 
were of analytical grade, used without further purification and purchased from Merck Chemicals 
(Germany). Purified water used during the study was produced in the laboratory with a Milli-Q 
purification system (Millipore corp., USA). Nutrient Broth, Mueller-Hinton Broth (MHB) and 
Mueller-Hinton Agar (MHA) were obtained from Biolab (South Africa). The bacterial cultures 
used were Staphylococcus aureus ATCC 25923 and methicillin-resistant Staphylococcus aureus 
(MRSA) (Staphylococcus aureus Rosenbach ATCC BAA 1683). Optical density (OD) was 
measured using a Mindray MR-96A microplate spectrophotometer (China). FT-IR spectra of all 
the compounds were recorded on a Bruker Alpha-p spectrometer with diamond ATR (Germany) 
as per standard protocols.  1H NMR and 13C NMR measurements were performed on a Bruker 
400/600 Ultrashield™ (United Kingdom) NMR spectrometer. HRMS was performed on a Waters 
Micromass LCT Premier TOF-MS (United Kingdom). 
Synthesis of dendron 4 (Scheme 1) 
The G1 PETIM dendron with a carboxylic acid function at the periphery was synthesised by 
hydrolysis of the dendron as reported in the literature 47. In summary, a mixture of 3-amino-1-
propanol 1 (5 g; 67 mmol) in methanol (20 ml) was added drop wise to a solution of tert-butyl 
acrylate 2 (51.2 g; 399 mmol) in methanol (100 ml), and was stirred for 6 h at room temperature. 
Surplus tert-butyl acrylate and solvent were removed in vacuo, with the crude product obtained 
being diluted with dichloromethane and washed with brine (3 x 25 ml). The organic layer was 
dried over anhydrous sodium sulphate and concentrated to yield 3 as a clear colourless liquid (21 
g; 96%). Acetyl chloride (0.95 g; 12 mmol) and water (0.22 ml; 12 mmol) were added to a solution 
of 3 (0.5 g; 1.5 mmol) in dichloromethane (30 ml), and the solution was stirred at room temperature 
for 8 h. Solvents were removed under vacuum to afford 4 as a viscous material (0.3 g; 91%). FT-
IR (neat) ν: 2959, 1712, 1399, 1179, 929 cm-1. 1H NMR (400MHz, CD3SOCD3) δ: 1.82 (q, 2H), 
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2.50 (t, 4H), 2.82 (t, 2H), 3.47 (t, 4 H), 3.76 (t, 2H). 13C NMR (100MHz, CD3SOCD3) δ: 28.3, 
37.0, 52.2, 58.9, 59.0, 174.4. HRMS (ES-TOF): [M]+ calcd for C9H17NO5 220.1185; found 
220.1181. 
Synthesis of G1 PETIM dendrimer with an aromatic core 7 (Scheme 2) 
A mixture of 3 (3 g; 9 mmol) and DMAP (3.3 g; 27 mmol) in PhMe (60 ml) was refluxed for 3 h 
and cooled to room temperature. 1,3,5-benzenetricarbonyl trichloride 5 (0.6 g; 2.3 mmol) was then 
added to the mixture and the reaction was refluxed for 6 h. PhMe was removed in vacuo and the 
crude product was purified via column chromatography (silica, mesh size 60-100) hexane/EtOAc, 
4:6) to obtain 6 as a colourless oil (1.5 g; 60%). Acetyl chloride (3.63 g; 46 mmol) and water (0.73 
ml; 41 mmol) were added to a solution of 6 (1.06 g; 0.92 mmol) in dichloromethane (40 ml), and 
the resulting solution was stirred vigorously at room temperature for 8 h. Solvents were then 
removed in vacuo and the subsequent residue was triturated with dichloromethane and hexane to 
obtain 7 (0.7 g; 93%) as a white foamy solid. FT-IR (neat) ν: 2601, 1710, 1232, 1402, 944, cm-1. 
1H NMR (400MHz, CD3SOCD3) δ: 2.23 (b, 6 H), 2.86 (t, 12H), 3.29 (t, 6H), 3.36 (t, 12H), 4.44 
(t, 6H), 8.70 (s, 3H). 13C NMR (100MHz, CD3SOCD3) δ: 22.8, 28.3, 50.6, 52.1, 62.9, 131.28, 
134.3, 167.5, 174.1. 
Synthesis of G1 PETIM dendrimer with an oxygen core 12 (Scheme 3) 
Acrylonitrile 8 (11.66 g; 0.22 mmol) was added drop wise to aqueous sodium hydroxide (40%) (2 
ml), while maintaining the temperature below 30 °C. The reaction mixture was stirred overnight 
at room temperature and then neutralized with hydrochloric acid (32%) (w/w). The product was 
extracted with chloroform (3x50 ml) and washed with 5% sodium hydroxide (100 ml) followed 
by brine (50 ml). The organic layer was dried over anhydrous sodium sulphate and concentrated 
under vacuum to yield 9 (7.44 g; 55%). To a solution of LiAlH4 (1.38 g; 48 mmol) in dry THF (40 
ml) at 0 °C, 9 (3 g; 24 mmol) was added drop wise, a solution of 9 in THF (10 ml). The reaction 
was allowed to come to room temperature and was then stirred for 1 h, after which cold water (2.2 
ml; 122 mmol) was added drop wise to the reaction mixture. The reaction mixture was stirred 
overnight at room temperature to afford 10, a diamine (2.63 g; 80%) after filtration of the reaction 
mixture and evaporating the solvent. A solution of 10 (2.63 g; 20 mmol) in methanol (60 ml) was 
added drop wise to tert-butyl acrylate (14.02 g; 0.11 mmol) in methanol (50 ml), and the reaction 
was stirred for 6 h at room temperature. After column chromatographic purification (silica, mesh 




size 60-100) (hexane/EtOAc, 7:3) and removal of the solvents, 11 was obtained as a colourless 
liquid (3.45 g; 27%). Finally, acetyl chloride (1.33 ml; 15 mmol) and water (0.28 ml; 16 mmol) 
were added to a solution of 11 (0.5 g; 0.77 mmol) in dichloromethane (10 ml), and the solution 
was stirred vigorously at room temperature for 8 h to afford 12 (0.3 g; 94%) after removing the 
solvent in vacuo and trituration of residue with hexane and dichloromethane several times. FT-IR 
(neat) ν: 2931, 1707, 1240, 1400, 930 cm-1. 1H NMR (400MHz, D2O) δ: 2.0 (b, 4H), 2.88 (t, 8H), 
2.93 (b, 4H), 3.31 (b, 4H), 3.47 (t, 8H). 13C NMR (100MHz, D2O) δ: 22.50, 2.28, 52.08, 58.9, 
62.7, 176.5. 
Silver salt of G1 PETIM dendron 13 
To a solution of 4 (0.1 g; 0.46 mmol) in methanol (10 ml), an aqueous solution of silver nitrate 
(0.154 g; 0.9 mmol) in H2O (5 ml) was slowly added and stirred vigorously for 2 h. The solvents 
were removed in vacuo to obtain 13 (0.19 g; 96%). FT-IR (neat) ν: 3028, 1722, 1633, 1284 cm-1. 
Silver salt of G1 PETIM dendrimer with an aromatic core 14 
An aqueous solution of silver nitrate (0.25 g; 0.31 mmol) in H2O (30 ml) was slowly added to a 
solution of compound 7 (0.2 g; 1.18 mmol) in methanol and stirred vigorously for 2 h. The solvents 
were removed in vacuo to obtain 14 (0.33 g; 92%).  FT-IR (neat) ν: 3019, 1713, 1287, 1233, 1181 
cm-1. 
Silver salt of G1 PETIM dendrimer with an oxygen core 15 
Compound 12 (0.25 g; 0.59 mmol) was dissolved in acetone (50 ml), to which an aqueous solution 
of silver nitrate (0.405 g; 2.38 mmol) in H2O (30 ml) was slowly added and stirred vigorously for 
2 h. The solvents were removed in vacuo to afford 15 (0.5 g; 99%). FT-IR (neat) ν: 2932, 1714, 
1265, 1210 cm-1. 
 
In vitro cytotoxicity study 
Cell culture against hepatocellular carcinoma (Hep G2), colorectal adenocarcinoma (HT-29) and 
breast adenocarcinoma (SK-BR-3) cell lines were cultured with complete medium (minimum 
essential medium, supplemented with 10 % bovine calf serum, 100 units/ml of penicillin, and 100 




mg/ml of streptomycin). Cells were maintained at 37 ˚C in a humidified atmosphere of 5% CO2 in 
air. 
Solutions: The compounds were dissolved in DMSO and distilled water as a stock solution 62, and 
diluted in the culture medium at concentrations of 20, 40, 60, 80 and 100 µg/ml as working-
solutions. 63 
MTT assay: The cell lines were harvested from the exponential phase were seeded equivalently 
into a 96-well plate (2.2 x 103) and incubated for 24 h to allow for adherence. Thereafter, the 
culture medium was removed and replaced with fresh medium (100 µl per well), with the samples 
being added to the wells to achieve final concentrations. The control wells were prepared by adding 
the culture medium only. Wells containing the culture medium without cells were used as blanks. 
All experiments were performed with six replicates. Upon completion of the incubation for 48 h, 
the culture medium and compounds were removed and replaced with fresh medium (100 µl) and  
100 µl of MTT solution (5 mg/ml in PBS) in each well. After 4 h incubation, the media and MTT 
solution was removed and 100 µl of DMSO was added to each well to solubilize the MTT 
formazan. The OD of each well was measured on a microplate spectrophotometer at a wavelength 
of 540 nm 64. The percentage cell viability was calculated as follows: 
% cell survival = [A540 nm treated cells] / [A540 nm untreated cells] X 100  (1) 
(A540: absorbance at a wavelength of 540 nm) 
Antimicrobial evaluation 
Determination of minimum inhibitory concentrations (MICs): The MICs of the PETIM 
dendron/dendrimers, silver nitrate and dendrimer-silver salts were determined in triplicate using 
the broth dilution method.  Stock solutions of 4 (0.4 mg/ml), compound 7 (0.44 mg/ml) and 12 
(0.38 mg/ml), as well as silver nitrate in three different concentrations (0.60 mg/ml, 0.56 mg/ml, 
0.62 mg/ml), were prepared in dimethyl sulfoxide (DMSO). The quantities were equivalent to the 
amount of individual components present in 1 mg/ml solutions of the respective dendrimer-silver 
salt. Stock solutions of the various dendrimer-silver salts (1 mg/ml) were prepared in distilled 
water 13 and DMSO 14 and 15. The compounds were tested against S. aureus and MRSA, which 
were grown overnight in Nutrient Broth at 37° C and adjusted to 0.5 McFarlands standard with 
distilled water. Serial dilutions of the dendron/dendrimers, silver nitrate and dendrimer-silver salts 




were prepared in MHB from the stock solutions. The test bacteria were added to each dilution and 
incubated overnight at 37 °C. Thereafter, each dilution was spotted on MHA plates and incubated 
overnight at 37° C.  After incubation, the MHA plates were examined for growth and the MIC’s 
was determined, with DMSO being used as a control. 
Determination of fractional inhibitory concentration (FIC): The effects of the combination of G1 
PETIM dendron/dendrimers and silver nitrate were investigated by determining the Ʃ FIC. The 
European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society 
of Clinical Microbiology and Infectious Diseases (ESCMID) 65 described the method for 
quantifying MIC results in terms of the FIC index, defined as the sum of FIC values of two drugs 
in combination. An example of the method used to calculate the ƩFIC is as follows:  
For two antibacterials A and B alone and in combination (4 and silver nitrate) 
FIC(A) = MIC(A in presence of B)         (2) 
 MIC(A alone) 
           = 52.08 
               500 
           = 0.10416 
FIC(B) = MIC(B in presence of A)         (3) 
 MIC(B alone) 
           = 52.08 
112.5 
= 0.46293 
ƩFIC = FIC(A) + FIC(B)         (4) 
= 0.10416 + 0.46293 
= 0.56709 
 
The FIC index is shown in Table 3. Indifference is when the effect of a combination of 
antimicrobials is equal to the effects of the most active compound. The additive effect refers to the 
effect of a combination of antimicrobials, where the effect of the combination is equal to that of 
the sum of the effects of the individual components. Synergistic action of a combination of two 




antimicrobials is present if the effect of the combination exceeds the additive effects of an 
individual compound. 65 
 
Table 3. FIC index. 65 
Index Synergy Additive Indifference Antagonism 
FIC ≤ 0.5 > 0.5 – 1 >1 to < 2 ≥ 2 
 
Statistical analysis 
The results are expressed as mean ± standard deviation (SD) and were analysed using one-way 
analysis of variance (ANOVA), followed by the Mann-Whitney test using GraphPad Prism® 
(Graph Pad Software Inc. Version 5, San Diego, CA). A p value of less than 0.05 was considered 
to be statistically significant. 
Conclusion 
The results obtained in the present study confirm the enhanced antimicrobial activity of the 
PETIM-silver salts at low concentrations against both S. aureus and MRSA. These results also 
demonstrate that the PETIM-silver salt with the highest number of Ag+ ions, had the greatest 
antibacterial activity. At the same time these salts display low cytotoxicity, which paves the way 
to synthesise silver salts of higher generation PETIM dendrimers, and to evaluate them as effective 
antimicrobials against a range of sensitive and resistant micro-organisms. A combination of such 
antimicrobial agents increases the spectrum of organisms that can be targeted and circumvent the 
emergence of resistance in microorganisms. The synthesized G1 PETIM-silver salts in this study 
show potential for applicability in pharmaceutical as well as biomedical fields. 
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CHAPTER 4. SUBMITTED MANUSCRIPT 
4.1 Introduction 
The following paper was submitted to an international ISI journal and reports the original 
research from data generated during this study: 
Suleman, N., Kalhapure, R., Mocktar C., Rambharose, S., Govender, T., 2015. A poly 
(ethylene glycol) six-arm star-shaped polymer as an efficient stabiliser for the synthesis of 
antibacterial and non-cytotoxic silver nanoparticles. RSC Advances, SUBMITTED 
MANUSCRIPT. Reference number: RA-ART-11-2015-023113. (IF = 3.708) 
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Kalhapure assisted with the design of the project, as well as the interpretation of 
characterisation data of the synthesised materials in terms of IR, NMR and XRD. Dr C. 
Mocktar assisted with the in vitro antimicrobial study. Mr S. Rambharose assisted with the in 
vitro cytotoxicity study. The remaining author served as supervisor. 
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4.2 Submitted manuscript 
A poly (ethylene glycol) six-arm star-shaped polymer as an 
efficient stabiliser for the synthesis of antibacterial and non-
cytotoxic silver nanoparticles 





Although silver nanoparticles (Ag NPs) are considered an attractive alternative for developing 
novel antibacterials, stability is a significant concern linked to their application as aggregation 
of NPs has been shown to considerably decrease their activity, leading to inferior performance. 
There is a lack of studies for the application of star polymers as stabilising agents for preparing 
colloidal Ag NPs. In this paper, we report on the synthesis of a generation 1 poly propyl ether 
imine (G1-PETIM) dendrimer derived 6-arm polyethylene glycol (PEG) star polymer (G1-
PETIM-mPEG SP) and its application as a stabiliser for Ag NPs. The G1-PETIM-m-PEG SP 
was characterised using Fourier-transform infrared spectroscopy (FT-IR), nuclear magnetic 
resonance spectroscopy (1H and 13C) and X-ray diffraction (XRD) analysis. Silver 
nanoparticles (G1-PETIM-m-PEG SP@Ag NPs) were prepared via chemical reduction using 
the G1-PETIM-m-PEG SP as a stabiliser, with their formation being verified using UV-vis 




spectroscopy, dynamic light scattering, transmission electron microscopy and XRD analysis. 
The G1-PETIM-m-PEG SP and G1-PETIM-m-PEG SP@Ag NPs were evaluated for their 
cytotoxicity against MCF-7, HeLa and Hep G2 cell lines using MTT assay. G1-PETIM-m-
PEG SP@Ag NPs, silver nitrate, G1-PETIM-m-PEG SP and a physical mixture of the latter 
two were evaluated for antibacterial activity against S. aureus, MRSA, E. coli and P 
aeruginosa. The synthesised G1-PETIM-m-PEG SP@Ag NPs were non-agglomerated, 
spherical and monodisperse, with an average particle size of 36.44 ± 2.51 nm, and found to be 
non-cytotoxic, even up to 100 µg/ml. The minimum inhibitory concentration values against S. 
aureus and MRSA (Gram-positive bacteria) were 18.5 and 74 µg/ml respectively, and against 
E.coli and P. aeruginosa (Gram-negative bacteria), the values were 9.25 and 74 µg/ml 
respectively. These low MIC values confirmed that Ag NPs retained their antibacterial 
potential even upon stabilisation by the G1-PETIM-m-PEG SP. The results obtained in this 
study suggest that the synthesised G1-PETIM-m-PEG SP is an attractive biocompatible star 
polymer for the stabilisation of Ag NPs. 
 
Keywords: star-shaped · poly (ethylene glycol) · stabiliser · silver nanoparticles · antibacterial 
· P. aeruginosa · methicillin-resistant S. aureus  
 
Introduction 
Noble metal nanoparticles have attracted attention owing to their distinctive properties 
and potential applications in numerous areas for instance sensors, medicine, catalysts and 
electronics.1-3 Various kinds of metal nanomaterials have been studied to date, however silver 
nanoparticles (Ag NPs) are reported as being the most effective and promising for biomedical 
and pharmaceutical use.4 This can be ascribed to their good antimicrobial efficacy against not 
only bacteria, but also viruses and other eukaryotic micro-organisms.4, 5 When compared to 
other antimicrobial agents, Ag is one of the most potent, displays a strong toxicity to a wide 
range of microorganisms and has a particularly low human toxicity.6-8 While elemental silver 
and silver salts have been recognised as antimicrobial agents in preventive and curative health 
care since ancient times,6 their use could cause unwanted adsorption of ions in the sweat glands 
and epidermal cells.6, 9, 10 Ag NPs therefore appears to be a better candidate compared to silver 
cation salts and complexes.6 Furthermore, the importance of Ag NPs as promising 
antibacterials lies in the fact that, unlike commercial antibiotics, they do not damage useful 
enzymes in the host.6 




Ag NPs have unique physical and chemical properties, and are considered to be an 
alternate for developing novel antibacterial agents. Furthermore, they have varied medical 
applications, such as coatings for medical devices, wound dressings, textile fabrics etc.4 
Bacterial resistance has also not yet been detected with the use of Ag NPs, due apparently to 
the difference in the mechanism of the antibacterial actions of the diverse forms of Ag.11-13  It 
is extremely unlikely that resistance to antimicrobial Ag might ever occur, since this would 
mean that an organism would have to undertake simultaneous mutations in each critical 
function in just a single generation to escape the compounds multiple actions.7, 14   
Despite the fact that Ag NPs have displayed good performance as antibacterials, a 
significant challenge currently linked to their application is identifying strategies to provide 
the satisfactory stability of their dispersions to prevent aggregation of the NPs. The 
generation of spacious aggregates shows a noteworthy drop in activity of NPs, which results 
in inferior performance and a loss of antibacterial activity.13, 15 Therefore, Ag NPs are 
frequently fabricated by the reduction of silver nitrate, and are then stabilised by capping 
agents to decrease the risk of aggregation, which arises from the high surface area of 
nanoparticles.15 To prevent particle agglomeration, numerous polymers have been 
investigated to stabilise these metal colloids.16 The polymers studied so far to stabilise Ag 
NPs include polyethylene glycols (PEG),17 poly(vinylalcohols) (PVA),18 
poly(vinylpyrrolidones) (PVP),19 polyacrylamides,20 polyurethanes (PU),21 as well as highly 
branched molecules, such as dendrimers,22 hyperbranched polymers,23 and star polymers.2 As 
polymers act as a kind of matrix, they have been extensively utilised for trapping NPs.24-26 
The search for new polymers as stabilising agents is therefore of great importance to facilitate 
their application as antimicrobials. 
Star polymers (SPs) are known as the simplest type of branched materials, wherein at 
least three linear polymer chains with essentially identical lengths are attached to only one 
branching point (core).27-29 These polymers can contain chemically identical or different arms 
(miktoarm) linked to the core.  They have enticed considerable attention owing to their unique 
topological structure and attractive physical and chemical properties, which are different from 
their linear counterparts.29, 30 Usually, SPs have reduced hydrodynamic dimensions, lower 
solution and melt viscosities than their linear counterparts as well as equal molecular weights.31, 
32 Moreover, they also comprise a higher degree of end group functionalities that are fairly 
important in specialised applications.33 Therefore, if the components of the SPs are 
biodegradable and/or biocompatible, these copolymers have potential biomedical applications, 




such as drug/gene delivery, tissue engineering, diagnosis, medical devices, and 
antibacterial/antifouling biomaterials.29, 30 These SPs could be a novel family of stabilising 
agent for preparing colloidal Ag NPs. Although an amphiphilic modified hyperbranched 
polyethyleneimine polymer has been used to stabilise Ag NPs and displayed certain attractive 
advantages, for instance, the quasi-spherical branched assembly with numerous inner cavities 
and nearly nonexistence of chain entanglements,34 very few SPs, particularly water-soluble 
SPs, have been utilised as stabilising agents so far.2, 23, 32  
PEG has been documented as fairly effective for attaining protein resistant surfaces.35-
37 Furthermore, PEG is non-toxic and non-immunogenic, which can be an added benefit for 
its use in biomedical and pharmaceutical applications.36 Incorporating PEG into SPs is of 
recent interest in the literature.37 Cross linked multi-arm star PEG systems have proven to be 
particularly successful at not only avoiding protein adsorption, but also in preserving the 
functional form of proteins, specially immobilised on surfaces coated with these polymers. 
Star PEG systems are attractive to confer protein resistance to surfaces because of their dense 
core structures. The high density of reactive groups on the surface of SPs can also be 
advantageous, for instance, in attaining a high binding capacity on surfaces giving 
immunoreactive groups to antibodies.37-39 Although PEG proposes numerous advantages, its 
properties have not been widely reported for producing Ag NPs, and there are only a handful 
of papers reported to have used PEG as a stabilising and/or reducing agent to produce Ag 
NPs.17, 40, 41 Finally, although PEG/dendrimer star polymers have been synthesised and 
applied previously,42, 43 according to our knowledge, thus far they are yet to be utilised as 
stabilising agents for the preparation of metal NPs.  
In this study, we therefore designed and synthesised a novel six-arm star-shaped PEG 
polymer using a generation 1 (G1) poly propyl ether imine (PETIM) dendrimer. In the present 
investigation, m-PEG, as well as the synthesised G1-PETIM-m-PEG SP, were evaluated as 
stabilising agents for producing Ag NPs. The particles were evaluated in terms of their 
DLS,TEM, UV visible spectroscopy, XRD, cytotoxicity assay and antimicrobial properties to 
assess their potential as stable and non-agglomerated NPs with effective antibacterial activity 








Tert-butyl acrylate and 3-amino-1-propanol were purchased from Alfa Aesar, (Germany). 4-
(dimethylamino) pyridine (DMAP), 1,3,5-benzenetricarbonyl trichloride, lithium aluminum 
hydride (LiAlH4), poly (ethylene glycol) methyl ether (Mn = 5000g/mol) (m-PEG), sodium 
borohydride (NaBH4), sodium hydride (NaH) (60% dispersion in mineral oil), sodium sulfate, 
silica gel and silver nitrate (AgNO3) were purchased from Sigma-Aldrich (USA). Thionyl 
chloride and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were 
procured from Merck (Germany). All other reagents and solvents were of analytical grade and 
used without further purification. Purified water used throughout the studies was produced in 
the laboratory with a Milli-Q water purification system (Millipore corp., USA). Nutrient Broth, 
Mueller-Hinton Broth (MHB) and Mueller-Hinton Agar (MHA) were obtained from Biolab 
(South Africa). The bacterial cultures used were Staphylococcus aureus ATCC 25923, 
methicillin-resistant Staphylococcus aureus (MRSA) [Staphylococcus aureus Rosenbach 




Fourier transmission infrared spectroscopy (FT-IR) 
FT-IR spectra of all the compounds were recorded on a Bruker Alpha-p spectrometer with 
diamond ATR (Germany) as per standard protocols. 
 
Nuclear magnetic resonance (NMR) 
1H NMR and 13C NMR measurements were performed on a Bruker 400/600 Ultrashield™ 
(Germany). 
 
Synthesis of G1 PETIM-ester 1 
A mixture of 3-amino-1-propanol (5 g; 67 mmol) in methanol (20 ml) was added drop wise to 
a solution of tert-butyl acrylate (51.2 g; 399 mmol) in methanol (100 ml), and was stirred at 
room temperature for 8 h. Excess tert-butyl acrylate and solvent were removed in vacuo, with 
the crude product obtained being diluted with dichloromethane and washed with brine (75 ml). 
The organic layer was dried over anhydrous sodium sulfate and concentrated to yield clear 
colourless ester (21 g; 96%). A mixture of the ester (3 g; 9 mmol) and DMAP (3.3 g; 27 mmol) 
in toluene (60 ml) was refluxed for 3 h and cooled to room temperature. 1,3,5-
benzenetricarbonyl trichloride (0.6 g; 2.3 mmol) was then added to the mixture and the reaction 




was refluxed for 6 h. Toluene was removed in vacuo, and the crude product was purified by 
column chromatography (silica, mesh size 60-100; hexane/EtOAc, 4:6) to obtain G1 PETIM-
ester 1 as a colourless oil (1.5 g; 60%). FT-IR (neat) ν: 2976, 1721, 1366, 1233, 1148, 950 cm-
1. 1H NMR (400 MHz, CDCl3) δ: 1.43 (s, 54H), 1.96 (q, 6H), 2.38 (t, 12H), 2.57 (t, 6H), 2.77 
(t, 12H), 4.42 (t, 6H), 8.83 (s, 3H).  
 
Synthesis of G1 PETIM-alcohol 2 
A solution of LiAlH4 (1.32 g; 34.78 mmol) in dried THF (40 ml) was added to a 2 neck round 
bottomed flask equipped with a guard tube and then flushed with N2 gas. A mixture of 
compound 1 (5 g; 4.34 mmol) in dried THF (20 ml) was cooled to 0°C  and added drop wise 
to the round bottomed flask, which was maintained at 0°C. On completion of the addition, the 
reaction mixture was stirred overnight at room temperature and thereafter slowly added to ice, 
dried with sodium sulfate and filtered. The filtrate was concentrated under vacuum to yield 
compound 2 (2.12 g; 67%). FT-IR (neat) ν: 3294, 1593, 1135, 1050 cm-1. 1H NMR (400 MHz, 
CDCl3) δ: 1.55 (m, 12H), 2.41 (m, 6H), 2.50 (m, 18H), 3.43 (t, 12H), 3.36 (b, 6H), 4.47 (m, 
6H), 8.50 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ: 29.79, 50.86, 59.54, 60.69, 62.97, 
122.89, 142.0, 169.6. 
 
Synthesis of G1-PETIM-chloride 3 
Thionyl chloride (5.9 g; 49.59 mmol) was added drop wise to a mixture of compound 2 (2 g; 
2.74 mmol) in dry dichloromethane (50 ml) and the reaction was refluxed overnight. Thionyl 
chloride was removed in vacuo using a NaOH trap and the crude product 3 was used for further 
reaction. FT-IR (neat) ν: 2960, 1248, 1730, 653 cm-1. 1H NMR (400 MHz, DMSO-d6) δ: 1.83 
(m, 6H), 2.19 (m, 12H), 2.49 (bs, 12H), 2.53 (bs, 6H), 3.75 (t, 12H), 4.81 (bs, 6H), 9.65 (s, 
3H). 
 
Synthesis of G1-PETIM-m-PEG SP 4 
A mixture of m-PEG (35.6 g; 7.12 mmol) in dried THF (60 ml) was added to a round bottomed 
flask, NaH (0.33g; 13.75 mmol) was added to it and stirred for 30 min. The reaction was then 
heated to 80°C and compound 3 (0.98g; 1.17 mmol) was added dropwise. On completion of 
the addition, the reaction was refluxed for 24 h. The reaction material was concentrated under 
vacuum to remove excess solvent and then recrystallised in acetone to yield compound 4. FT-
IR (neat) ν: 2881, 1466, 1359, 1146, 1099 cm-1. 1H NMR (400 MHz, D2O) δ: 1.83 b (-O-CH2-




CH2-CH2-N-), 3.30 s (-CH2-O-CH3), 3.45 b (-N-CH2-CH2-CH2-O-), 3.62 b (-O-CH2-CH2-O-
), 3.80 b (-CH2-N-(CH2)2), 4.55 b (Ar-COO-CH2-), 7.32 s (Ar-H). 13C NMR (100 MHz, D2O) 
δ: 46.66, 58.15, 60.48, 62.50, 65.37, 69.69, 72.51, 74.00, 76.88, 100.01, 127.85, 138.25. 
 
Preparation of silver nanoparticles 
10 ml of AgNO3 (0.01M) was added drop wise to the G1 PETIM-m-PEG SP (0.17 g; 0.006 
mmol) in water (25 ml) under magnetic stirring at room temperature. After completion of the 
addition, 1.5 ml of NaBH4 (0.1 M) was added dropwise to the mixture under vigorous stirring. 
The reaction mixture was further stirred for 10 min. To synthesise m-PEG@Ag NPs, m-PEG 
was used instead of G1 PETIM-m-PEG, and for plain Ag NPs, this was done without any 
stabiliser following the same procedure. 
 
UV analysis  
The surface plasmon resonance (SPR) of the silver nanoparticles was monitored by UV-visible 
spectroscopy. To confirm the reduction of silver ions, the solution was scanned in the range of 
200–700 nm (Shimadzu 1650PC, Japan) using a quartz cuvette with water as the reference. 
The solution was obtained by diluting 1 ml of silver nanoparticles in 30 ml of water. 
 
Particle size (PS), polydispersity index (PDI) and zeta potential (ZP) 
The average PS, PDI and ZP were determinedby Dynamic Light Scattering (DLS) using a 
NanoZS Zetasizer (Malvern Instruments Corp., UK) at 25 °C with a path length of 10mm in 
polystyrene cuvettes. 200 μl of each sample was diluted with 10 ml of distilled water. The 
analysis consisted of three measurements in triplicate for each sample and results were 
expressed as mean size ± S.D. 
 
Transmission Electron Microscopy (TEM) 
The size and morphology of the silver nanoparticles were examined using a transmission 
electron microscope (Jeol JEM-2100, Japan). The sample was prepared by placing a drop of 
Ag NPs on carbon-coated copper grid and thereafter allowed to dry in air before being 








Powder X-ray diffraction (XRD) 
 
Powder XRD patterns were obtained using a Bruker D8 Advance Diffractometer (Germany) 
equipped with a graphite monochromator operated at 40 kV and 40 mA. The radiation source 
was a CuKα X-ray source with λ = 1.5406 Å. Data was collected at a step of 0.021 ° and at a 
scanning speed of 0.454 ° s-1. The 2θ range covered was between 10 ° to 90 °.  
 
In vitro cytotoxicity study 
Cell culture: Human breast cancer (MCF-7), HeLa and Hepatocellular carcinoma (Hep G2) 
cell lines were cultured with complete medium (minimum essential medium, supplemented 
with 10 % bovine calf serum, 100 units/ml of penicillin, and 100 mg/ml of streptomycin). Cells 
were maintained at 37 ˚C in a humidified atmosphere of 5% CO2 in air. 
Solutions: The test compound was dissolved in distilled water as a stock solution,44 and diluted 
in the culture medium at concentrations of 20, 40, 60, 80 and 100 μg/ml-1 as working 
solutions.45 
MTT assay: The cells harvested from the exponential phase were seeded equivalently into a 
96-well plate (2.2 x 103) and incubated for 24 h to allow for adherence. Thereafter, the culture 
medium was removed and replaced with fresh medium (100 µl per well), with the sample being 
added to the wells to achieve final concentrations. The control wells were prepared by adding 
the culture medium only. The wells containing the culture medium without cells were used as 
blanks. All experiments were performed with six replicates. Upon completion of the incubation 
for 48 h, the culture medium and compounds were removed and replaced with fresh medium 
(100 µl) and  100 µl of MTT solution (5 mg/ml in PBS) in each well. After 4 h incubation, the 
media and MTT solution was removed and 100 µl of DMSO was added to each well to 
solubilize the MTT formazan. Optical density (OD) was measured using a Mindray MR-96A 
microplate spectrophotometer (China). The OD of each well was measured on a microplate 
spectrophotometer at a wavelength of 540 nm.46 The percentage cell viability was calculated 
as follows: 
% cell survival = [A540 nm treated cells] / [A540 nm untreated cells] X 100  (1) 









Determining the minimum inhibitory concentrations (MICs): The MICs of the G1 PETIM-m-
PEG SP, AgNO3, G1 PETIM SP@Ag NPs and a mixture of SP and AgNO3 were determined 
using the broth dilution method.  The quantities were equivalent to the amount of individual 
components present in the final SP@Ag NP solution. The compounds were tested against S. 
aureus, MRSA, E.coli and P. aeruginosa. The bacterial cultures were grown overnight in 
Nutrient Broth at 37 °C and adjusted to 0.5 McFarlands standard with distilled water. Serial 
dilutions of the test materials were prepared in MHB from the stock solutions. The test bacteria 
were added to each dilution and incubated overnight at 37 °C. Thereafter, each dilution was 
spotted on MHA plates and incubated overnight at 37° C.  After incubation, the MHA plates 
were examined for growth to determine the MICs. 
 
Stability studies 
The stability of the optimised G1 PETIM-m-PEG SP@Ag NPs was evaluated at room 
temperature (RT) and at 4 ºC over a period of three months. The physical appearance, PS, PDI 
and ZP were used as assessment parameters for stability. 
 
Statistical analysis 
The results expressed as mean ± standard deviation (SD) were analysed using one-way analysis 
of variance (ANOVA), followed by the Mann-Whitney test using GraphPad Prism® (Graph 
Pad Software Inc. Version 5, San Diego, CA). A p value of less than 0.05 was considered 
statistically significant. 
  
Results and discussion 
Synthesis  
The synthesis of G1 PETIM-ester 1 was accomplished by following the literature reported 
procedure.14, 47 In short, dendron with primary alcohol as a focal functionality was prepared 
using a Michael addition reaction between 3-amino-1 propanol and tert-butyl acrylate. This 
dendron was then condensed with 1,3,5-benzenetricarbonyl trichloride  in the presence of 
DMAP to obtain tert-butyl ester terminated G1 PETIM dendrimer 1.  The lithium aluminium 
hydride (LiAlH4) mediated reduction of 1 was followed by a subsequent reaction of formed 
G1-PETIM dendrimer-OH 2 with thionyl chloride (SOCl2) afforded G1 PETIM dendrimer-Cl 




3. Finally, 3 was coupled to m-PEG in the presence of NaH to afford a six-arm G1 PETIM-m-









Scheme 1 Synthesis of G1 PETIM-m-PEG SP 
 
Characterisation  
The techniques used to characterise the intermediates and G1-PETIM-m-PEG SP were FT-IR 
and NMR (1H and 13C). The formation of G1 PETIM-ester 1 was confirmed by comparing the 
analytical data with literature data.47 The conversion of tert-butyl ester of 1 to alcohol to form 
G1-PETIM-OH was confirmed by the disappearance of an ester peak at 1721 cm-1 and the 
appearance of an alcohol peak at 3294 cm-1 in FT-IR; disappearance of ester protons from 1.43 
δ ppm and shift of adjacent –CH2- peak from 2.57 δ ppm to 1.55 δ ppm in 
1H NMR due to 
shielding by formed alcohol function at the periphery.  In the 13C NMR, the ester carbons 
disappeared at 80.3 and 171.7 δ ppm, and the shift in –CH2-C=O-  carbon from 33.8δ ppm to 
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50.85 δ ppm was due to the formation of –CH2-CH2-OH in 
13C NMR. The peak around 653 
cm-1 in the FT-IR spectra of the G1-PETIM-chloride (Fig. S1, Supporting Information)  is 
attributed to C-Cl stretching vibrations that appear in the range from 730-550 cm-1.48 The C-Cl 
stretch, along with the disappearance of the O-H stretching band in the 3400-3200 cm-1 region, 
confirmed the formation of the G1-PETIM-chloride. Finally, the formation of the G1 PETIM-
m-PEG SP was confirmed by a disappearance of –C-Cl stretch at 653 cm-1 and the appearance 
of a strong –C-O- ether stretch at 1099 cm-1 in FT-IR (Fig. S2; Supporting Information). The 
characteristic peaks in 1H NMR of G1 PETIM-m-PEG SP were of –CH2-O- at 3.56 δ ppm, -
CH2-N- peak at 3.80 δ ppm and terminal –O-CH3 at 3.23  δ ppm (Fig. S3; Supporting 
Information), whereas in 13C NMR, they were terminal –O-CH3 at 60.48 δ ppm, -C=O- ester 
at 138.25 δ ppm and aromatic carbons at 100 and 127.84 δ ppm (Fig. S4; Supporting 
Information). 
Synthesis and characterisation of G1 PETIM-m-PEG SP@Ag NPs 
Synthesis of plain Ag NPs, m-PEG Ag NPs and G1 PETIM-m-PEG SP@Ag NPs was 
accomplished via chemical reduction using sodium borohydride (NaBH4). Upon complete 
addition of NaBH4, the transparent solution formed aggregates (Fig 2) in the case of the plain 
Ag NPs and m-PEG Ag NPs. However, the transparent solution converted to a brown coloured 
dispersion for the SP coated NPs, indicating the formation of G1 PETIM-m-PEG SP@Ag NPs. 
For the plain Ag NPs and m-PEG Ag NPs, the intensity of the SPR peak was very low, which 
could be due to the incomplete formation of Ag NPs followed by aggregation (Fig. 1a and 1b). 
Aggregation of the plain and m-PEG Ag NPs can be clearly seen in Fig. 2. The peak at a 
wavelength of 394.30 nm in the UV-visible spectra due to surface plasmon resonance (SPR) 
of the electrons in the conduction band of Ag further confirmed the formation of G1 PETIM-
m-PEG SP@Ag NPs.49, 50 The symmetric and markedly narrow shape of the plasmon band 
(Fig. 1c) indicated that the G1 PETIM-m-PEG SP@Ag NPs were monodisperse and spherical 
in shape.50, 51  





 Fig. 1 (a) UV-visible absorption spectra of plain Ag NPs, (b) UV-visible absorption spectra of 
m-PEG Ag NPs and (c) UV-visible absorption spectra of G1 PETIM-m-PEG SP Ag NPs. 
  
Fig. 2 Images of: (a) plain Ag NP, (b) G1 PETIM-m-PEG SP@Ag NP and m-PEG@Ag NP 
solutions.  





Particle size, polydispersity index, zeta potential and morphology  
To assess the size and morphology of the Ag NPs, DLS and transmission electron microscopy 
(TEM) studies were performed. Results from the DLS studies indicated extremely large 
particles sizes of 1870 nm ± 829.0 and 1025 nm ± 246.1, and PDIs of 0.864 ± 0.166 and 0.662 
± 0.120 for plain Ag and m-PEG@Ag NPs respectively. It was observed through TEM 
investigations that aggregates had formed in the plain and m-PEG@Ag NPs (Fig 4 and 5). This 
proved the inefficiency of m-PEG on its own to stabilise formed Ag NPs. However, for G1 
PETIM-m-PEG SP@Ag NPs, a particle size of 36.44 nm ± 2.51 with a PDI of 0.414 ± 0.007 
was observed. TEM studies then confirmed that the G1 PETIM-m-PEG SP@Ag NPs were 
non-agglomerated, and spherical in shape with uniform particle size in the range of 25-30 nm 
(Fig. 3). The ZP for G1 PETIM-m-PEG SP@Ag NPs was found to be -23.7 ± 2.47, this 
negative value for ZP showing good stability of the NPs.  
Noble metal NPs have been synthesised in various sizes, compositions and shapes.52 
Although Ag NPs have been reported to be as small as 1 nm, and it has been shown that particle 
size as well as shape can have an effect on antimicrobial activity, 4, 53 Ag NPs in the range of 1 
– 100 nm have demonstrated strong bactericidal activity against both Gram positive and Gram 
negative bacteria, with our NPs being well within this size range.53, 54 Stabilised NPs have also 
been shown to have varying sizes and shapes, depending on the type of stabilising agent used.13 
Popa et al prepared PEG stabilised Ag NPs in sizes ranging from 4 – 50 nms,17 whereas Huang 
et al prepared Ag NPs stabilised by an amphiphilic star-shaped copolymer with a size range of 
between 10 – 20 nms.2 The literature shows that considerably enhanced activity has been noted 
for stabilised Ag NPs when compared to their unmodified counterparts.13 Therefore, our G1 
PETIM-m-PEG SP@Ag NPs is within the range of effective NP sizes according to literature.53, 
54 




              
 
Fig. 3 TEM images of: (a) plain Ag NPs, (b) m-PEG@Ag NPs and (c) G1 PETIM-m-PEG 
SP@Ag NPs; inset shows a single G1 PETIM-m-PEG SP@Ag NP. 
 
XRD analysis 
The XRD pattern of lypophilised G1 PETIM-m-PEG SP@Ag showed peaks at 2θ values of 
38.3, 44,4, 64,4, 77.6, 81.6o which were characteristic peaks of Ag NPs, representing the 111, 
200, 220, 311 and 222 Braggs reflection of the face-centered cubic (fcc) structure of silver. The 
2θ values were in good agreement with previously reported values for Ag NPs.55, 56 The 
presence of two prominent peaks of G1-PETIM-m-PEG SP at 2θ values of about 19.3 and 23.4 
confirmed that G1 PETIM-m-PEG SP@Ag was stabilised by the G1 PETIM-m-PEG SP (Fig. 
4a-b). 




   
Fig. 4 XRD patterns of (a) G1 PETIM-m-PEG SP and (b) G1 PETIM-m-PEG SP@Ag NPs. 
 
In vitro cytotoxicity studies 
The cellular response to a compound can be determined via cytotoxicity assays that deliver 
information about cell death and their metabolic activities.57 MCF-7, HeLa and Hep G2 cell 
lines are widely used to assess the biocompatibility of newly synthesised materials for diverse 
applications.58-60 The safety of the G1 PETIM-m-PEG SP and G1 PETIM-m-PEG SP@Ag NPs 
in biological studies was therefore established by an in vitro cytotoxicity study on MCF-7, 
HeLa and Hep G2 cell lines using the MTT assay.  The cytotoxicities of AgNO3, G1 PETIM-
m-PEG SP, and G1 PETIM-m-PEG SP@Ag NPs were based on the biochemical reduction of 
MTT by viable cells.61  AgNO3 displayed a cell viability in the range of 59.91% to 30.97% 
against all the studied cell lines, indicating its toxicity to mammalian cells in a concentration 
dependant manner. There was a statistically significant decrease (p < 0.05) in cell viability by 
AgNO3 across all the cell lines studied when compared to their respective controls. The results 
were supportive of previous findings, where AgNO3 had significantly reduced  cell viability 
with increasing concentration62, which further supports the fact that silver is known to be non-
toxic to human cells in minor concentrations.4, 63 Cell viability across all the cell lines was 
98.37% to 75% and 87.39% to 70.47% for the G1 PETIM-m-PEG SP and G1 PETIM-m-PEG 
SP@Ag NPs respectively, within the concentration range studied (Fig. 5). The results further 
indicated that the effects of the synthesised compounds on the cell lines were not dose 
dependent, as no dose dependent trends were observed for either G1 PETIM-m-PEG SP or G1 
PETIM-m-PEG SP@Ag NPs (Fig. 5) compared to that of AgNO3. However, with the exception 




of the G1 PETIM-m-PEG SP at 80µg/ml and the G1 PETIM-m-PEG SP@Ag NPs at 40µg/ml 
against HeLa cells, there were no other statistically significant differences observed for the 
remaining cell lines at any of the concentration studied. The results displayed statistically 
significant differences for the G1 PETIM-m-PEG SP and G1 PETIM-m-PEG SP@Ag NPs, 
however, the cell viability was greater than 75%. This data suggests that the G1 PETIM-m-
PEG SP and G1 PETIM-m-PEG SP@Ag NPs could be considered safe.64, 65 The range of cell 
viability attained in this study also specifies that the G1 PETIM-m-PEG SP and G1 PETIM-
m-PEG SP@Ag NPs exhibited a low toxicity level on all chosen cell lines.14, 64 These findings 
therefore demonstrate the biocompatibility of the synthesised G1 PETIM-m-PEG and biosafety 
of G1 PETIM-m-PEG SP@Ag NPs.  





























Fig. 5 (a) Cytotoxicity assay on MCF-7 cell lines displaying percentage cell viability after 
exposure to AgNO3 and various concentrations of the G1 PETIM-m-PEG SP and G1 PETIM-
m-PEG SP@Ag NPs. The results are presented as mean ± SD. (n = 6). *denotes significant 
difference compared to the untreated control (p < 0.05). 

































(b) Cytotoxicity assay on HeLa cell lines displaying percentage cell viability after exposure to 
AgNO3 and various concentrations of the G1 PETIM-m-PEG SP and G1 PETIM-m-PEG 
SP@Ag NPs. The results are presented as mean ± SD. (n = 6). * denotes significant difference 
compared to the untreated control (p < 0.05). 


































Fig. 5 (c) Cytotoxicity assay on Hep G2 cell lines displaying percentage cell viability after 
exposure to AgNO3 and various concentrations of the G1 PETIM-m-PEG SP and G1 PETIM-
m-PEG SP@Ag NPs. The results are presented as mean ± SD. (n = 6). * denotes significant 
difference compared to the untreated control (p < 0.05). 
 
In vitro antimicrobial studies  
The antimicrobial activity of AgNO3, G1 PETIM-m-PEG SP, a mixture of AgNO3 and G1 
PETIM-m-PEG SP, and G1 PETIM SP@Ag, NPs were investigated against  S. aureus, 
methicillin-resistant S. aureus (MRSA) [Gram positive], and E. coli and P. aeruginosa (Gram 
negative). A summary of the results for the minimum inhibitory concentration (MIC) values 
for in vitro antimicrobial activity is presented in Table 1. 
 
Table 1 MIC results for in vitro antimicrobial activity of G1 PETIM-m-PEG SP, AgNO3, a 
mixture of the G1 PETIM-m-PEG SP and AgNO3, and G1 PETIM-m-PEG SP@Ag NPs 





S. aureus MRSA E. coli P. aeruginosa 
G1 PETIM-m-PEG SP - - - - 
Ag NO3  0.58 18.5 9.25 18.5 
Mixture of G1 PETIM-m-PEG SP and Ag NO3 37 18.5 4.62 18.5 
G1 PETIM-m-PEG SP@Ag NPs 18.5 74 9.25 74 
 
The G1 PETIM-m-PEG SP displayed no antimicrobial activity against all the bacterial 
strains used in this study. AgNO3 was found to be the most effective amongst all other materials 
tested, having the best activity against S. aureus (0.58 µg/ml), followed by the physical mixture 
of AgNO3 and the G1 PETIM-m-PEG SP.  This is due to the fact that ionised silver induces 
structural changes in the bacterial cell walls and nuclear membranes, as it is extremely reactive 
once it binds to tissue proteins. Consequently, it leads to cell distortion and ultimately cell 
death. Additionally, Ag ions can bind to bacterial DNA and RNA, and can hence inhibit 
bacterial replication. However, these antimicrobial properties of Ag are reliant on the amount 
and rate at which Ag is released.4, 66 Despite the potent antimicrobial activity of Ag, it is vital 




to note that silver is non-toxic to human cells only in minute concentrations,63 which clearly 
restricts the use of Ag ions in the form of AgNO3, or any other salt as antibacterial agents.
14  
When compared to AgNO3, although the MICs of the G1 PETIM-m-PEG SP@Ag NPs 
were higher, they were within the ranges of previously reported MIC values for Ag NPs against 
S. aureus,67 MRSA,68 E. coli 53 and P. aeruginosa.69 The G1 PETIM-m-PEG SP@Ag NPs 
therefore enjoys the advantage of being less toxic than AgNO3, and is more stable than the 
uncapped Ag NPs.  
The MIC values of the G1 PETIM-m-PEG SP@Ag NPs against S. aureus and MRSA 
were 18.5 and 74 µg/ml respectively, whereas against E.coli and P. aeruginosa, the values 
were 9.25 and 74 µg/ml respectively. The lowest MIC against E. coli displayed a 
considerable difference when compared to the other bacterial strains tested. This may be 
attributable to the cell wall composition of E. coli. Gram-negative bacteria having just a thin 
peptidoglycan layer (∼2–3 nm) between the cytoplasmic membrane and the outer 
membrane,70 whereas the Gram-positive bacteria lack the outer membrane and have a much 
thicker peptidoglycan layer of approximately 30 nm.71 The thick peptidoglycan layer of 
Gram-positive bacteria could have prevented an uptake of silver ions in the cytoplasm, while 
the less thick wall of the Gram-negative bacteria could have facilitated the fast internalisation 
of G1 PETIM-m-PEG SP@Ag NPs in the cell wall, subsequently changing the DNA into a 
condensed form. The internalised G1 PETIM-m-PEG SP@Ag NPs would then have 
interacted with the thiol groups in the proteins, leading to structural changes in the protein 
and eventually cell death.4, 72 Ag NPs are reported to have excellent antibacterial activity 
against E. coli.73 When bacteria such as E. coli are treated with metal NPs, the bacterial 
membrane displays a noteworthy increase in permeability, leaving the bacterial cells unable 
to properly regulate transport through the plasma membrane, inevitably results in cell death. 
It is commonly known that the outer membrane of E. coli cells are principally fabricated from 
tightly packed lipopolysaccharide molecules, which proposes an effective permeability 
barrier.73, 74 Metal depletion can result in the development of irregular shaped pits in the outer 
membrane and altered membrane permeability, which is a result of the progressive release of 
liposaccharide molecules and membrane proteins.75 We can therefore speculate this as being 
the reason the G1 PETIM-m-PEG SP@Ag NPs having the best activity against  E. coli.73 
However, P. aeruginosa, although a Gram-negative bacteria, displayed an MIC value 
greater (low potency) than the Gram-positive S. aureus. This could be due to the differences 
between the cell walls of E. coli and P. aeruginosa. A general outer membrane permeability 




of P. aeruginosa is 12 – 100 fold lower than E. coli. 76 This low outer membrane 
permeability, along with a secondary resistance mechanism such as efflux, could be the 
reasons for the high MIC value of G1 PETIM-m-PEG SP@Ag NPs against P. aeruginosa. 76  
Finally, the MIC value of 74 µg/ml against MRSA states/proves that the synthesised 
G1 PETIM-m-PEG SP@Ag NPs are efficient enough to inhibit the growth of drug resistant 
bacteria, and could therefore be an attractive delivery system to treat infections by MRSA. 
 
Stability studies  
The results from stability studies on G1 PETIM-m-PEG SP@Ag NPs are presented in Table 2. 
There were no statistically significant changes (p > 0.05) in PS, PDI and ZP between NPs 
stored at 4 °C and RT over a period of three months.  In addition, no change in physical 
appearance and colour was noticed throughout the study period. The results confirmed the 
stability of G1 PETIM-m-PEG SP@Ag NPs under all specified storage conditions.    
 
Table 2 Effect of storage condition on particle size, PDI and ZP. 
Storage 
conditions 
Particle size (nm) PDI ZP 
Time (days) 4 °C RT 4 °C RT 4 °C RT 
















































*PS, PDI and ZP are expressed at mean, n=3.  
 
Conclusion  
G1 PETIM-m-PEG SP is a novel and biocompatible material which proved to be an efficient 
stabilising agent for the synthesis of Ag NPs. The results obtained in this study revealed that 
synthesised G1 PETIM-m-PEG SP@Ag NPs was an effective antimicrobial agent against 
Gram-positive, Gram-negative and drug-resistant bacteria with low toxicity to eukaryotic cells. 
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The applicability of the six-arm star-shaped G1 PETIM-m-PEG star polymer in drug delivery 
systems can further be exploited by its use in the preparation of surface modified 
nanoparticulate drug delivery systems, which can bypass phagocytic blood clearance, and 
ultimately increase the blood circulation time.   
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CHAPTER 5. REVIEW ARTICLE 
5.1 Introduction  
The following review paper was published in an international ISI journal: 
Kalhapure, R.S., Suleman, N., Mocktar, C., Seedat, N., Govender, T., 2014. Nanoengineered 
Drug Delivery Systems for Enhancing Antibiotic Therapy. Journal of Pharmaceutical Sciences, 
3, 872-905. (IF = 2.59) 
Ms. N Suleman contributed to the literature searches as well as the collection and compilation 
of review papers and all research papers with regard to nano antibiotic delivery systems. Ms N 
Suleman also contributed to writing part of the introduction.  
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CHAPTER 6. CONCLUSIONS 
6.1 General conclusions 
Although antibiotics are essential for treating and managing infectious diseases, numerous 
disadvantages of current conventional dosage forms limit their efficacy. Alternative novel 
antimicrobial therapeutic strategies are being explored to address the imminent crisis with 
conventional antibiotics. However, as studies on novel antimicrobial systems are still in the early 
stages, it is necessary to identify novel materials for formulation optimisation in this field.  
The research described in this thesis is intended to address the difficulties associated with current 
antibiotic therapy, and explores the use of novel polymeric materials to overcome the challenges 
related to antimicrobial resistance. The aim of the study was to: (1) explore the potential of novel 
antimicrobial dendrimer silver salts for enhanced antimicrobial activity and (2) explore the 
potential of a novel star shaped polymer for use as a stabilising agent in the preparation of silver 
nanoparticles. The work reported in this thesis accomplished the aim of this study and generated 
the following conclusions: 
 Objectives 1 – 4: In addressing the first aim of this study, G1 PETIM dendron and two
PETIM dendrimers containing a carboxylic acid function at the periphery were
successfully designed and synthesised using reported methods. They were then used as
templates to contain the silver ions, after which the PETIM dendron/dendrimers were
reacted with silver nitrate to form PETIM-silver salts by means of simple techniques of
mechanical stirring and solvent evaporation using a rotovap. These synthesised PETIM
dendron/dendrimers were then characterised in terms of FT-IR and NMR, and the PETIM-
silver salts were characterised in terms of FT-IR only, due to the hygroscopic nature of the
salts. The FT-IR peaks in the range of 1459-1332 cm-1 from carboxylic acid terminated
dendron and dendrimers disappeared, and the appearance of symmetric stretching
vibrations in the range of 1288-1233 cm-1 was observed after transforming them into their
respective silver salts. Thus, the presence of the bands due to symmetric stretching
vibrations of the equivalent carbon-oxygen bonds strongly confirmed the formation of
PETIM-silver salts. The cytotoxic effects of the salts were evaluated in terms of MTT
assay, and the range of cell viability obtained indicated that the PETIM-silver salts
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displayed a low toxicity level on all the cell lines studied. Additionally, the effects of the 
compounds on the cell line were not dose dependent, as no such trends were observed for 
any of the PETIM-silver salts at the various treatment concentrations against any of the 
cell lines.  These PETIM-silver salts also displayed a greater percentage cell viability when 
compared to their respective concentrations of silver nitrate. In vitro antimicrobial testing 
revealed the enhanced antimicrobial activity of the PETIM-silver salts at low 
concentrations against both S. aureus and MRSA, and that the G1 PETIM-silver salt with 
the highest number of carboxylic acid functions, and ultimately the highest number of Ag+ 
ions, had the greatest antibacterial activity. The data attained for these objectives confirmed 
for the first time the potential of PETIM silver salts as non-toxic antimicrobial agents 
against sensitive and resistant bacteria. 
 For Objective 5 – 7, a biocompatible and biodegradable novel G1 PETIM-m-PEG star
shaped polymer was successfully designed and synthesised using a core first approach.
This synthesised star polymer was then characterised in terms of IR, 1H NMR, 13C NMR,
and XRD analysis. The formation of the G1 PETIM-m-PEG star polymer was confirmed
by a disappearance of –C-Cl stretch at 653 cm-1 and the appearance of a strong –C-O- ether
stretch at 1099 cm-1 in FT-IR. The characteristic peaks in 1H NMR of G1 PETIM-m-PEG
star polymer were of –CH2-O- at 3.56 δ ppm, -CH2-N- peak at 3.80 δ ppm and terminal –
O-CH3 at 3.23  δ ppm, whereas in 
13C NMR, those were terminal –O-CH3 at 60.48 δ ppm,
-C=O- ester at 138.25 δ ppm, and aromatic carbons at 100 and 127.84 δ ppm. The cytotoxic
effects of the star polymer was assessed using the MTT assay, and the range of cell viability
attained, specified that the PETIM-m-PEG star polymer displayed a very low toxicity level
on all the cell lines studied. Furthermore, the effects of the compound on all the cell lines
was not dose dependent, as no such trends were observed. The data attained was then used
for the preparation of silver nanoparticles.
 Objectives 8 – 10, involved preparing silver nanoparticles using the G1 PETIM-m-PEG
star polymer as a stabilising agent, via chemical reduction using NaBH4, their formation
being confirmed by UV-visible spectra and XRD analysis. The peak at a wavelength of
394.30 nm in the UV-visible spectra, due to surface plasmon resonance (SPR) of the
electrons in the conduction band of silver, confirmed the formation of G1 PETIM-m-PEG
star polymer silver nanoparticles. In terms of XRD, the 2θ values were in agreement with
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previously reported values for silver nanoparticles. TEM and DLS studies were performed 
to determine the particle size, PDI and morphology of the silver nanoparticles. The DLS 
studies indicated a particle size of 36.44 ± 2.51, with a PDI of 0.414 ± 0.007, while the 
TEM studies confirmed that the nanoparticles were spherical, of uniform particle size, non-
agglomerated and well dispersed in the size range of between 25-30 nm. The cytotoxic 
effects of the star polymer stabilised nanoparticles were also assessed, and the range of cell 
viability attained, which indicated similar results to that of the star polymer itself. A low 
toxicity level on all the cell lines studied was seen, and the effects of the compound on the 
cell line was not dose dependent, as no such trends were observed. The in vitro 
antimicrobial tests revealed that the star polymer stabilised silver nanoparticles are efficient 
enough to inhibit the growth of sensitive and resistant bacteria, and could therefore be an 
attractive delivery system to treat a host of infections. 
In this study, novel materials and a nano-delivery system with the potential to improve antibacterial 
therapy were successfully prepared and characterised. The established formulation approaches and 
the thorough characterisation studies will benefit scientists exploring other methods of preparing 
novel antimicrobial systems. Further studies in this rapidly growing field will need a 
multidisciplinary approach to accomplish the best outcomes. 
6.2 Significance of the findings 
The significance of the results and outputs generated from this study are: 
Optimising treatment for infectious diseases: 
 With limited commercially available polymeric materials to help combat the growing
difficulties that arise from bacterial resistance, identifying novel polymeric materials for
antimicrobial systems as novel delivery systems is a valuable alternative to contend with
the issue of AMR. This study has confirmed the formation of new antimicrobial materials
and a novel delivery system, the PETIM silver salts and star polymer stabilised silver
nanoparticles, which display good antimicrobial activity against both sensitive and
resistant bacterial strains. These systems can improve the treatment of patients with various
bacterial infections, thereby enhancing patients’ quality of life and improving the economy
of the country.





Identifying new pharmaceutical materials: 
 This study identified PETIM silver salts and star polymer stabilised silver nanoparticles, 
which are new materials, with the potential for commercialisation. It expands the pool of 
materials for formulation scientists to develop novel antibacterial systems.  
Creating new knowledge on polymers for drug delivery systems: 
 New knowledge was obtained on the applicability and antimicrobial properties of PETIM 
dendron\dendrimers in particular, as our study confirmed the antimicrobial activity of these 
type of dendrimers for the first time.  
 New knowledge on the application of star polymers as stabilising agents for nanoparticle 
formation was obtained, this being the first study to utilise a six arm star shaped PEG 
polymer as a stabilising agent to prepare silver nanoparticles. 
Impact of this study on future research: 
 This study is the building block for future research such as TEM, in depth in vitro/in vivo 
antimicrobial studies, as well as molecular mechanistic studies to optimise these materials 
and delivery systems for commercial use in patients. It can also be explored for application 
in nanomedicine and the biomedical sciences.  
  
6.3 Recommendations for future studies  
This study has set the foundation for formulating novel antimicrobial delivery systems. Further 
studies are essential preceding commercialisation of these new agents and can be summarised as 
follows: 
 
PETIM silver salts: 
 In vitro and in vivo antimicrobial studies using both sensitive and resistant strains of Gram 
positive and Gram negative bacteria should be performed to test whether the silver salts 
have a wide range of activity against different types of bacteria. 
 In vivo antimicrobial studies using infected animals, and even human subjects, should be 
performed to test the silver salts antimicrobial effect. These studies may also offer details 
on bioavailability and related pharmacokinetics, which could provide insight into possible 
formulation adjustments that are essential to attain optimal bioavailability.  





 The differences in activity of the three PETIM-silver salts against S. aureus and MRSA 
could be due to differences in the structure and composition of their cell walls. However, 
no mechanistic studies are available in the literature using novel materials and delivery 
systems against S. aureus and MRSA. Molecular mechanistic simulations can be done on 
the silver salts to establish a correlation between the in vivo and in silico data. 
 A larger scale production technique could be designed to prepare the silver salts to enable 
the feasibility of the preparation method to be assessed for application in the 
pharmaceutical industry. 
 An additional characterisation method could be employed to not only assess the purity of 
the silver salts, but also to better understand the structural components of them. 
Silver nanoparticles: 
 Numerous metal ions, such as copper, gold, etc., could be used to assess whether or not the 
star polymer is a good stabiliser for other metal nanoparticles.  
 Further antimicrobial studies, such as the TEM analysis of bacteria, can be performed to 
establish the exact mechanism by which the nanoparticles affect bacteria. 
  In vivo antimicrobial studies using infected animals, and even human subjects, should be 
performed to test the silver nanoparticles in terms of their antimicrobial effect. These 
studies could also offer details on bioavailability and related pharmacokinetics, which 
could provide insight into possible formulation adjustments that could be essential to attain 
optimal bioavailability.  
 Molecular mechanistic simulations can be done on the silver nanoparticles to establish a 
correlation between the in vivo and in silico data. 
 A larger scale production method could be designed to establish the feasibility of preparing 
the silver nanoparticles for application in the pharmaceutical industry. 
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The identification of polymeric materials for stabilisa-
tion of silver nanoparticles (Ag NP) is essential for 
their optimal formulation and activity. Star polymers 
(SPs), wherein at least three linear polymer chains 
with essentially identical lengths are attached to only 
one branching point (Inoue, 2000) , have attracted 
considerable attention due to their unique topological 
structure and attractive physical and chemical proper-
ties which are different from their linear counterparts 
(Wu et al., 2015; Jia et al., 2014). These SPs could be 
a novel family of stabilising agents for the preparation 
of colloidal silver nanoparticles (Ag NPs). Despite 
their numerous advantages there is a lack of literature 
on the design, synthesis and application of SPs to pre-
pare stable Ag NPs for biomedical and pharmaceutical 
applications.  
In this paper we report, the synthesis of a novel gen-
eration 1 poly propyl ether imine (G1-PETIM) den-
drimer derived 6-arm polyethylene glycol (PEG) SP 
(G1-PETIM-mPEG SP) and its application as a stabi-
liser for Ag NPs. The G1-PETIM-mPEG SP was char-
acterised using Fourier-transform infrared spectros-
copy (FT-IR), nuclear magnetic resonance spectros-
copy (1H and 13C) and X-ray diffraction (XRD) anal-
ysis. Silver nanoparticles (G1-PETIM-m-PEG 
SP@Ag NPs) were prepared via chemical reduction 
using the G1-PETIM-m-PEG SP as a stabiliser and 
their formation was verified using FT-IR, UV-vis 
spectroscopy, dynamic light scattering, transmission 
electron microscopy and XRD analysis. The G1-
PETIM-m-PEG SP and G1-PETIM-m-PEG SP@Ag 
NPs were evaluated for their cytotoxicity against 
MCF-7, HeLa and Hep G2 cell lines using MTT assay. 
G1-PETIM-m-PEG SP@Ag NPs, silver nitrate, G1-
PETIM-m-PEG SP and a physical mixture of the latter 
two were evaluated for antibacterial activity against S. 
aureus, MRSA, E. coli and P. aeruginosa. The syn-
thesised G1-PETIM-m-PEG SP@Ag NPs were non-
agglomerated, spherical and monodisperse as com-
pared to Ag NPs prepared with m-PEG and without 
any stabilizer (Fig. 1a-c). The average particle size of  
G1-PETIM-m-PEG SP@Ag NPs was 36.44 ± 
2.51nm, and were found to be non-cytotoxic even up 
to 100 µg/ml. The minimum inhibitory concentration 
values against S. aureus and MRSA (Gram-positive 
bacteria) were 18.5 and 74 µg/ml respectively, and 
against E.coli and P. aeruginosa (Gram-negative bac-
teria), the values were 9.25 and 74 µg/ml respectively. 
These low MIC values proved that nanoparticles re-
tained their antibacterial potential upon stabilisation 
by the G1-PETIM-m-PEG SP. The results obtained in 
this study suggest that the synthesised G1-PETIM-m-
PEG SP is an attractive biocompatible star polymer 
for the stabilisation of Ag NPs. 
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Figure 1: TEM images of: (a) G1-PETIM-m-PEG 
SP@Ag NPs; inset shows a single SP Ag NP, (b) m-
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